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DEVELOPMENT OF HYALURONIC ACID-DERIVED MACROMOLECULAR
AGENTS FOR MULTIMODAL IMAGING PROBES AND NANOMEDICINE

William M Payne, Ph. D.
University of Nebraska, 2020
Supervisor: Aaron M. Mohs, Ph. D.
Cancer, one of the most challenging maladies facing modern medicine, is a
complex family of diseases that requires a multifaceted treatment regime. In recent years,
increased research effort has been placed on the development of nanoscale formulations
as a potential method to improve therapeutic efficacy and offer better treatment. Both drug
formulation and biomedical imaging has benefitted from the development of new,
nanoscale agents.
Hyaluronic Acid (HA), a naturally occurring glycosaminoglycan, is a promising
platform for the development of new drug delivery systems. Furthermore, hyaluronic acid
is the principal ligand for the cell surface receptor CD44, which is overexpressed on many
different cancer cells. For these reasons, HA is often used as a component in novel
formulations of anticancer therapies or biomedical imaging agents.
This work is divided into two sections: the first detailing the use of hyaluronic acidderived contrast agents for integrated preoperative and intraoperative imaging, and the
second part investigating the effects of hydrophobic modification on the dynamics of HA.
These two parts coalesce in the exploration of HA as a backbone of nanoformulations and
strive to improve the ability to use HA as a foundation of better formulations.
In the first part of this dissertation, a mixed micelle formulation comprised of both
fluorescent and paramagnetic labeled HA is used to provide higher contrast in a murine
model of breast cancer. The ratio of fluorescent and paramagnetic HA is optimized to
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provide contrast in fluorescence and magnetic resonance imaging. In the second part of
this dissertation, theoretical approaches using molecular dynamics simulation are
employed to better elucidate the behavior of hydrophobically modified HA.
The unifying theme of this dissertation is the enhanced understanding of HA-based
nanoformulations. Beginning with direct, experimental application, limitations are
discovered in the development of a multimodality imaging agent formulation using HA as
the backbone. Instigated by this limitation, theoretical approaches are employed to better
define and describe the foundational principals of nanoformulation using HA. Ultimately,
the work presented herein serves to further the ability to design, characterize, and apply
HA-based nanomedicines.
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Chapter 1: Introduction
Biomedical Imaging in Breast Cancer
As cancer continues to be one of the most common causes of death in the
developed world, improvements in the understanding and treatment of this family of
diseases continues to be a high priority in the international research community. Cancer
treatment is a complicated and arduous task, with modern treatment strategies including
the use of radiation therapy, chemotherapy, surgical intervention, and a variety of methods
for disease imaging and staging.1 Since the advent of X-ray imaging, efforts have been
made to better see inside the human body, leading to improved resolution, image quality,
and methods of acquiring images, giving rise to the field of biomedical imaging, a discipline
focused entirely on visualizing and mapping the human body, especially in regions of
pathology. Indispensable to this research effort is the development of imaging probes to
improve the contrast or signal obtained in imaging methods.
Cancer is a family of diseases in which imaging techniques provide much value to
physicians not only for diagnostic purposes, but also in surgical planning, disease staging,
and evaluation of treatment regimens.2,3 In this work, the development of new imaging
probes is presented for use in intraoperative and preoperative cancer imaging, with focus
on potential applications in breast cancer. The overarching goal of this project is to develop
imaging probes capable of providing superior guidance to surgeons in their attempt to plan
and execute resective surgery.
Breast cancer is among the most common forms of cancer today, with
approximately 235,000 cases being reported each year, 40,000 of them being fatal.1
Surgical intervention is a common treatment option, with secondary chemotherapy or
radiotherapy often being used to minimize recurrence.4 Although disease rates have been
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declining in recent years, recurrent disease presents a serious problem and is often
resistant to chemo- and radiotherapy.1 Improving the ability to not only detect but also
guide surgeons to remove malignant tissue through enhanced imaging probes, could
alleviate concern of recurrent disease.5,6

Preoperative Guidance and Surgical Planning
Biomedical imaging techniques have been used to plan surgeries for decades,
being used in cases ranging from broken bones to cancer resection. Obtaining images of
areas of interest prior to operation not only helps surgeons to identify the location of
pathologic tissue, but also to avoid causing damage to surrounding tissue. Advances in
preoperative planning have improved prognosis and ultimately survival rates, contributing
to the decline in cancer mortality.
Required
Molecular
Probe
Mass (Ng)

Modality

Form of
Energy
Used

Spatial
Resolution/Mm

PET

Annihilation
photos

1-2 (microPET);
6-10 (clinical
PET)

Minutes

1-100

SPECT

Gamma
rays

0.5-2
(microSPECT);
7-15 (clinical
SPECT)

Minutes

1-100

MRI

Radio
frequency
waves

0.01-0.1 (smallanimal MRI); 0.51.5 (clinical MRI)

Minutes
to hours

103-106

FI

Visible to
infrared
light

<1 (FRI); 1
(FMT)

Seconds
to
minutes
(FRI);
minutes
(FMT)

BLI

Visible to
infrared
light

3-5

US

High
frequency
sound
waves

0.04-0.1 (smallanimal US); 0.11 (clinical US)

Imaging
Time

Advantages

Imaging
Cost

Clinical
Translation

High
sensitivity;
quantitative;
tracer amount
of probe
High
sensitivity;
quantitative;
tracer amount
of probe
High spatial
resolution;
superb soft
tissue
discrimination

High

Yes

MediumHigh

Yes

High

Yes

10 -10

High
sensitivity;
multiplexed
imaging

Low
(FRI);
MediumHigh
(FMT)

Yes

Minutes

6

10 -10

High
sensitivity;
highthroughput

Low

No

Seconds
to
Minutes

103-106

High
sensitivity;
portable

LowMedium

Yes

3

3

6

Table 1: Summary of biomedical imaging techniques. Reproduced with permission.7
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The choice of imaging technique depends on disease pathology. The imaging techniques
which have emerged as popular options for preoperative planning are detailed in Table 1
above and summarized in the following Figure 1. Each different technique has advantages
and disadvantages, with some methods being preferred over others in certain cases at
the discretion of the attending physician. In all cases, contrast and images are obtained
through an energy vector, such as a paramagnetic ion in MR imaging or a radioactive
isotope in PET or SPECT imaging.
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Figure 1: Graphical overview of commonly used imaging techniques. Reproduced
with permission.13

Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a technique in which paramagnetic ions,
typically gadolinium (Gd3+) or manganese (Mn2+), are used as contrast agents.8 Using a
large magnet and a radiofrequency emitter, the patient is administered contrast agent
chelate, such as the FDA-approved Magnevist or Omniscan, and placed inside a circular
imaging system (in the center of the magnet). Radio waves at a frequency known as the
Larmour frequency cause rapid alignment and subsequent relaxation of the nuclei in water
molecules inside the body, a process that is expedited by the presence of contrast agent.
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This relaxation can be measured as a change in magnetic field, providing signal
proportional to the concentration of contrast agent.
Images are reconstructed to present a 3-dimensional construct comprised of
“slices” along an axis (typically along the vertebrate of the patient for whole body imaging).
The width between slices and resolution of features contained within each slice is subject
to optimization of both the imaging process (technical optimization) and contrast agent.

Positron Emission Tomography
Positron emission tomography is an imaging technique in which radioactive
isotopes provide contrast when undergoing degradation.7 PET requires the use of
radioactive components, and as such requires additional safety measures. Signal in PET
imaging is obtained after the degradation of a radioisotope. The radioisotope, often
fluorine-19 bound to a compound such as glucose, undergoes radioactive decay and emits
a positron. In near proximity, another positron is emitted, and the two positrons collide to
undergo an annihilation event. This annihilation event emits two gamma waves in at a
trajectory of 180° from each other. These gamma rays are subsequently detected by the
gamma counter detector on the PET imaging instrument. Using a Radon transform, the
exact position where the annihilation event occurred can be calculated, and this position
is used to construct the image.

State of the Art
In recent years, the efforts to improve on the available contrast agents have
produced a large body of research incorporating a wide range of agents, ranging from new
isotopes to nanoscale structures. Among these trends, the most notable has been in the
attention to macromolecular and nanoscale contrast agents, either composed of or
containing contrast-producing elements.9,10 In the broad field of nanomedicine, biomedical
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imaging has benefitted from the use of polymers to coordinate multiple paramagnetic ions
in the case of MRI, or solid particle constructs, such as transition metal-containing
nanocomposites or gold nanoparticles.11
The future of biomedical imaging is in the ability to combine different materials to
obtain functionality and signal in different imaging modalities. 7,12,13 Whereas conventional
and approved contrast agents are intended for use with a single imaging method, new
agents under development include the ability to be used in multiple imaging techniques.
These more advanced contrast agents are derived from novel materials, such as colloidal
nanoparticles or complex supramolecular structures. Figure 2 Illustrates the new
directions available in multimodality imaging.
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Figure 2: Nanoparticles for multimodal imaging. Reproduced with permission.12

Intraoperative Imaging for Surgical Guidance
Surgical resection remains the most promising treatment strategy for many forms
of cancer. Augmenting the efficacy of surgical intervention in cancer treatment through
technologies aiming to improve contrast, such as image-guided surgery, can improve the
prognosis and outcome of cancer treatment. 3,14,15 Residual cancerous tissue after surgery
contributes to tumor recurrence and is a limitation of surgical efficacy, reducing the
chances for long-term survival. Because surgeons are limited by what they can see and
feel,2 tumor recurrence resulting from positive margins and metastases presents an
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opportunity to increase survival.3 Thus, complete removal of cancerous tissue during the
initial surgical intervention is paramount to improve the prognosis for cancer patients.
Guidance during surgery for the detection of surgical margins and regional
metastases is not easily accomplished using conventional imaging techniques, such as
MRI, PET, or SPECT due to the necessity of large or not easily modularized
instrumentation.2 Fluorescence image-guided surgery (FIGS) has recently emerged as a
promising technique for intraoperative guidance. Contrast between malignant and healthy
tissue requires higher signal in the tumor than the surrounding, healthy or benign tissue.
As reported by our lab14,16,17 and others,15,18 the use of fluorescence contrast agents, both
FDA-approved (ICG) and experimental, can guide surgeons in real-time, delineating tumor
boundaries and improving outcome.3,15
Integrating an additional preoperative imaging technique such as MRI or CT with
FIGS could potentially improve surgical resection efficacy even more by defining margins
for preoperative planning or further guiding surgeons to regional metastases.19 Contrast
agents must have suitable pharmacokinetic parameters, limited toxicity, and high
sensitivity. To further improve the efficacy of FIGS, nanoparticle formulations are often
used to specifically target or achieve higher uptake in cancerous tissue.20–22
Nanoparticulate imaging agents have demonstrated superiority over combinations of
small molecules,13 and are also more versatile, allowing for the incorporation of targeting
moieties, drugs, and a larger variety of chemical modifications for functionality when
compared to small molecules. While inorganic nanoparticles have been used for various
imaging combinations, polymeric nanoparticles benefit from improved biocompatibility.13,23
The technologies enumerated in the previous section are available primarily for
preoperative imaging and are not suitable for intraoperative use. These techniques require
large machinery and contrast agent viability is often short-lived. In the case of MRI,
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contrast agents are quickly cleared by the body; in radioactive techniques, image
acquisition is limited by the half-life of the radioisotopes in use. Imaging during surgical
operation provides unique challenges in the restriction of viable equipment, but the ability
to detect malignant tissue in real-time during procedures presents great opportunity.

Fluorescence and Fluorescence Imaging
Due to restrictions on the available instrumentation, optical imaging techniques
have become favorable for use in intraoperative imaging. In addition to not needing large
equipment, the fact that the imaging area is readily in the field of view alleviates concern
over depth penetration of lasers. For these reasons, fluorescence imaging has risen as a
top choice of available modalities for intraoperative imaging.
The optics and imaging equipment behind both fluorescence and Raman
spectroscopy operate on similar principles: the detection of light after laser irradiation. In
biomedical applications, the laser used is typically of a near-infrared wavelength to
minimize tissue absorption. In the case of Raman, the light detected is inelastic scattering
of the incident light, demonstrating a lower energy (higher wavelength) than the laser. This
scattered light can be detected using a CCD camera and reported as signal.
Fluorescence is a phenomenon produced by certain molecules under irradiation
at a given wavelength in which light is emitted as a result of excited state relaxation. A
fluorescent molecule, when irradiated with laser light, absorbs a fraction of the light and
reaches an excited state. In this state, the electrons in the outermost orbital undergo a
relaxation event, and upon relaxing to a lower energy level, emit a photon at a lower
energy (higher wavelength) than the light originally absorbed. This emitted photon can be
collected using a CCD camera and reported as signal by the electronics in the instrument.
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Although raster imaging is possible using fluorescence (for example, in pre-clinical
imaging or fluorescence microscopy), the most common implementations of image-guided
surgery are to provide an overlay of signal on a near-field image from a traditional video
camera. In this setup, a spectrometer is used to both excite the region of interest and
collect signal from the imaging probes. Typical instrumentation can include a handheld,
pen-like spectrometer or an overhead devise suspended by adjustable arms. Table 2
presents an overview of fluorescence contrast agents currently under clinical and
preclinical development.
Fluorophore
Indocyanine
Green

Excitation/Emission
Wavelength
807/822 nm

Methylene
Blue

665/686 nm

Irdye800cw

774/789 nm

NonSulfonated
Cyanine Dyes
(Cyx Series)
Zwitterionic
Cyanine Dyes

747/774 nm (Cy7)
788/808 nm (Cy7.5)

Tissue Targets

Applications

Phase

Plasma
lipoprotein and
atheromas;
mostly nonspecific

Cardiovascular and
lymphatic angiography; bile
duct and GI tract imaging;
tumour imaging and IGS

FDA-approved*

Cardiovascular and
lymphatic angiography; bile
duct, GI tract and ureter
imaging; tumour imaging
and IGS

FDA-approved

Tumour imaging and IGS

Phase I

Structural and functional
imaging of tumour and other
tissues and organs

Mostly preclinical†

Non-specific
Non-specific;
conjugatable
with targeting
ligands
Non-specific;
conjugatable
with targeting
ligands

772/788 nm (ZW800-1)

αvβ3 (with RGD)

Tumour imaging

Phase I

Phosphonated
Cyanine Dyes

771/796 nm (Pam78)
785/802 nm (P800SO3)

Bone and microcalcification
imaging

Preclinical

Quaternary
Ammonium
Cyanine Dyes

666/692 nm (C700OMe) 770/804 nm
(C800-OMe)

Hydroxyapatite
deposits and
bone tissues
Cartilage tissues

Cartilage imaging

Preclinical

Bodipy

643/673 nm (mPB)
649/723 nm (BAP-5)

Tumour and Alzheimer’s
disease imaging

Preclinical

Conjugated
Copolymers

500–1,100/ 700–1,400
nm

Structural and
haemodynamic imaging of
blood vasculature, lymph
nodes and tumour

Preclinical

AggregationInduced
Emission Dots

511/671 nm (TPE-TPAFN AIE dot)‡

In vivo cell

n/a

Cardiovascular and
lymphatic angiography;
tumour and skeletal
imaging; lymph-node
mapping; visualization of
cell migration; in vivo
thermometry

Preclinical

Quantum Dots

Declining broadband
absorption/ 700–1,500
nm emission

Non-specific
(mPB) Amyloid
beta plaque
(BAP series)
Non-specific;
conjugatable
with targeting
ligands
Non-specific;
conjugatable
with targeting
ligands
Non-specific;
conjugatable
with targeting
ligands
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360/810 nm (Au)

Non-specific;
conjugatable
with targeting
ligands

Infrared
Fluorescent
Proteins

690/711 nm (IFP2.0)
674/703 nm (miRFP703)

Liver (with
adenovirus
vector) or
specific
molecular
targets

Single-Walled
Carbon
Nanotubes

550–1,050 nm
multiband/ 1,000–1,800
nm multiband

Non-specific;
conjugatable
with targeting
ligands

Rare-Earth
Nanoparticles

808 or 980/ 1,000–1,600
nm

Ir–Peg
Nanoparticles

808 or 980/ 900–1,400
nm

Ch1055

808/1,055 nm

Metal
Nanoclusters

Non-specific;
conjugatable
with targeting
ligands
Non-specific;
conjugatable
with targeting
ligands
EGFR+ tumour
with anti-EGFR
affibody

Imaging of tumour, kidney
clearance kinetics and
kidney dysfunction
Imaging of liver, brain
tumour, myoblast
differentiation, muscle
regeneration, cancer
metastasis, signalling
cascade, cell cycle and
specific protein labelling
Imaging of internal organs,
tumour, limb and brain
vasculatures, lymphatic
vessels and lymph nodes,
bacterial infection and nitric
oxide

Preclinical

Preclinical

Preclinical

Imaging of blood
vasculature, internal organs
and tumour

Preclinical

Imaging of blood
vasculature and internal
organs

Preclinical

Imaging of blood and
lymphatic vasculatures,
brain tumour and xenograft
EGFR+ tumour

Preclinical

Table 2: Near-infrared fluorescence contrast agents. Reproduced with permission.24

The Near-Infrared Window for Biomedical Imaging
Upon observing the excitation and emission wavelengths for the imaging probes
presented in Table 2, most probes are targeted for excitation and emission maxima in the
near-infrared range. Figure 3 demonstrates graphically the rationale for the use of nearinfrared wavelengths in biomedical imaging; due to the optical properties of tissue, the

Figure 3: Absorption and scattering profiles of biological samples. Reproduced with
permission from Upputuri and Pramanik.25
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most effective wavelengths for imaging are in the near-infrared window spanning between
700 nm and 1000mn.25 Furthermore, as shown in Figure 3B, the scattering profiles for
multiple tissue types show less scattering in the NIR-I region.
The absorption and scattering of light is the primary limitation for depth penetration
for any optical imaging technique in a biomedical context.24 In contrast, using wavelengths
too far into the NIR-II range limits the power and thus signal obtained from fluorescent
probes.26 Therefore, when developing a new fluorescent probe for biomedical use, most
efforts are concentrated in the NIR-I region.

Contrast Agents for Intraoperative Imaging
Fluorescence imaging of any kind requires a fluorescent contrast agent. Typically,
such agents are organic molecules of comparable size and properties to that of drugs and
contain numerous aromatic and pi-conjugated groups. In fluorescence microscopy,
numerous agents of various emission wavelengths ranging from ultraviolet to infrared are
available, and some of these fluorophores have been used in preclinical imaging studies.
Recently, the field of nanotechnology has produced new fluorescent agents,
including inorganic quantum dots. However, due to the inherent toxicity of heavy metals,
quantum dots have yet to reach the clinic. Additional contrast agents have been
demonstrated in preclinical studies using other heavy metals such as bismuth and
selenium, as well as organic nanostructure like carbon dots that exhibit fluorescent
properties. While some of these fluorescent structures may be less toxic that quantum
dots, the use of such agents has not progressed beyond preclinical research.
In this project, fluorescence imaging was chosen as the method of preoperative
imaging. The first efforts at contrast agent development conducted in the lab saw the
invention of NanoICG, a self-assembled nanoparticle formulation of the FDA-approved
ICG. As a near-infrared dye, ICG has an excitation maximum of 795, making it suitable for
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use in physiological environments. Using a custom-built IGS platform, positive results
were initially shown by Tanner Hill, Ph.D. in a breast tumor xenograft model.27
NanoICG, the first-generation contrast agent developed by the lab for use in FIGS,
is comprised of ICG encapsulated inside hydrophobically modified hyaluronic acid.
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan predominantly associated
with the extracellular matrix.28 As a natural biopolymer, HA-based formulations benefit
from higher biocompatibility. Furthermore, CD44, the principal cellular receptor for HA, is
known to be over-expressed in several forms of cancer, particularly breast cancer.29
Hyaluronic acid was modified with three different hydrophobic ligands to induce selfassembly, and ICG was loaded via dialysis.
Following these studies in FIGS, the lab has since made progress using different
formulations and different fluorophores to improve tumor specificity and signal obtained.
One such direction has been the use of different fluorophores, such as Cyanine-7.5 or IR800, two different near infrared fluorophores that demonstrate better quantum yield than
ICG. Furthermore, rather than entrapping these molecules in self-assembled
nanoparticles, as is the case with NanoICG, dyes were covalently attached to the
hyaluronic acid backbone. Covalent attachment altered the pharmacokinetic properties of
the contrast agent and presented opportunity to investigate the use of HA-based contrast
agents without hydrophobic modification or self-assembly.

Integrated Intraoperative and Preoperative Imaging
Given the advantages and drawbacks of both preoperative and intraoperative
imaging techniques, it becomes apparent that a combination of multiple imaging
modalities could improve surgical efficacy. Multimodality imaging is defined as the use of
different technologies in sequence or tandem to collect images in different ways. For
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example, combining CT imaging with intraoperative fluorescence imaging would provide
the benefits of high resolution for planning with real-time detection in the operating room
as previously demonstrated.

30,31

To this end, recent studies in biomedical imaging have

used nanotechnology to provide contrast in multiple imaging techniques.
In cancer, imaging is important not only to plan surgical intervention but also to
determine clinical stage and evaluate disease progression. Furthermore, since cancer is
a progressive disease and can metastasize to other regions of the body, locating and
identifying malignant tumors is increasingly important at later disease states. Residual
cancerous tissue, a consequence of positive margins, remaining after surgical intervention
significantly increases the risk of recurrent disease.32 Effective surgical intervention seeks
to remove all malignant tissue with minimal damage to normal tissue, and image-guided
surgery offers potential to assist surgeons in this aim.
Designing an agent to produce contrast in multiple imaging modalities is non-trivial,
since the difference in signal acquisition between techniques means that conventional
contrast agents are unsuitable when used alone and unmodified. For example, while
gadolinium provides contrast in MRI, no clinically approved MRI contrast agent is
fluorescent or radioactive. Because of this innate limitation in available contrast agents,
nanocomposites, macromolecule contrast agents, and nanoparticles (both hard and soft)
have drawn attention as platforms for developing new contrast agents.33
Modification of naturally occurring or biocompatible polymers with moieties for
contrast, such as radioisotopes, fluorophores, or gadolinium can produce stable,
biocompatible multimodal imaging agents. We have recently reported on the use of
hyaluronic acid-derived nanoparticles for imaging16,17,27 and drug delivery.34 However,
these HA nanostructures were primarily developed for intraoperative imaging.
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In this project, we hypothesize that the use of hyaluronic acid-derived formulations
for multimodality imaging will provide better contrast in vivo than currently available
contrast agents. Building from the prior work on hyaluronic acid formulations, a new
contrast agent known as Self-Assembled Multimodality Imaging Nanoparticles (SAMINs)
is developed. These formulations are hypothesized to be better than an inorganic
nanoscale construct (such as quantum dots) due to innate biocompatibility and the high
quantum yield of organic dyes. In the following chapters, two generations of SAMINs are
presented, with the first generation using a self-assembled formulation to provide contrast
in MRI and FIGS, and the second to provide contrast in PET and FIGS.
In this study we report the optimization of an HA-based nanoparticle formulation
for integrated preoperative MRI and intraoperative near infrared fluorescence imaging. HA
is a naturally occurring glycosaminoglycan that, when modified with hydrophobic moieties,
can self-assemble into nanoparticles.35–37 By conjugation of a fluorescent dye and Gd(III),
the modified HA polymers provide contrast for both fluorescence and MR imaging,
respectively. Furthermore, the ratio of fluorophore to paramagnetic agent can be tuned for
optimal fluorescence and MR contrast.
Herein, we synthesize a new formulation of HA-based contrast agents. We then
demonstrate efficacy in vitro by characterizing the contrast obtained in different tissue
phantom models and characterizing non-malignant cell response to the contrast agents.
Finally, the SAMINs are shown to produce contrast in MR and fluorescence imaging,
providing proof of concept for integrated preoperative and intraoperative imaging. We
demonstrate that HA-based nanoparticles incorporating both gadolinium and a
fluorophore can provide contrast enhancement for both imaging modalities, with the goal
of providing better surgical guidance for tumor resection and ultimately improving
prognosis.
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Chapter 2: Experimental
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Materials and Methods
1-Pyrenebutyric acid, diethylenetriaminepentaacetic acid (DTPA), 1,3-diaminopropane, Nhydroxysuccinimide, 1-ethyl-3-(3-dimethylamino)propyl)carbodiimide (EDC), gadolinium (III)
chloride, and xylenol orange were purchased from Sigma-Aldrich (St. Louis, MO).
Dimethylsulfoxide (DMSO), Methanol, N,N-dimethylformamide (DMF), concentrated hydrochloric
acid (HCl), concentrated nitric acid, 1X phosphate-buffered saline (PBS), and molecular sieves
(type 3A) were purchased from Fisher Scientific (Pittsburgh, PA). Ethanol was purchased from
UNMC internal supply. Sodium hyaluronate (HA) was purchased from Lifecore Biomedical
(Chaska, MN). Matrigel was purchased from BD Biosciences (San Jose, CA). Cy7.5-amine was
purchased from Lumiprobe Corporation (Hallandale Beach, FL).
Conjugation of aminopropyl-1-pyrenebutanamide to HA

Aminopropyl-1-pyrenebutanamide (PBA) was synthesized from 1-pyrenebutyric acid as
previously described.17,27 PBA-modified HA (HA-PBA) was synthesized by dissolving 90-95 mg
HA (MN = 10-20 kDa) in 1:1 DMF:H2O. NHS and EDC were added to the HA solution in 10-fold
molar excess and allowed to mix for 30 minutes. PBA (5-10 wt%) was first dissolved in 5 mL DMF,
then added dropwise to the HA solution and allowed to react for 24 h at room temperature. The
reaction mixture was then dialyzed against 1:1 EtOH:H2O for 24 h (4 exchanges) and water alone
for 48 h (8 exchanges). The HA-PBA product was then lyophilized and stored at -20 °C.

Conjugation of Cy7.5-amine to PBA-modified HA
Cy7.5-amine was conjugated to the amphiphilic PBA-modified HA as previously described
by Kelkar, et al.6 Briefly, PBA-HA (18.0 mg) was dissolved in 10 mL of 1:1 DMSO:H2O. NHS and
EDC were added to the PBA-HA solution and stirred for 30 minutes at room temperature to
activate the carboxylic acid groups of HA. A stock Cy7.5-amine solution in DMSO was prepared
and added dropwise to the HA reaction solution for a total of 2.0 mg Cy7.5. The reaction was
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covered to protect from light and allowed to proceed for 24 h under constant stirring at room
temperature. The product was purified through dialysis against ultrapure water for 24-36 h (8
exchanges). After dialysis, any remaining excess dye was removed with PD10 desalting columns
using ultrapure water as the mobile phase. Finally, the HA-PBA-Cy7.5 product was lyophilized
and stored at -20 °C, referred to hereon as HA-Cy.

Synthesis of paramagnetic amphiphilic HA
Addition of gadolinium to amphiphilic HA-PBA was accomplished by first conjugating DTPA
to HA via dianhydride hydrolysis and coordination with Gd3+ was achieved based on a method
reported by Moon, et al.38 Briefly, DMSO was first dried over molecular sieves to remove any
water. HA-PBA (50 mg) was then dissolved in the dry DMSO over 24 h, with bath sonication to
assist dissolution if needed. The solution remained cloudy but would become transparent after
reaction with DTPA dianhydride. After the HA-PBA was sufficiently dissolved, DTPA dianhydride
(25 mg, 0.07 mmol) was dissolved in 10 mL of dry DMSO and added dropwise to the HA-PBA
solution. The reaction was then allowed to proceed at room temperature for 48 h. The HA-PBADTPA product was then purified by dialysis against ultrapure water for 24-36 h (8 exchanges) and
lyophilized. To synthesize paramagnetic HA derivatives, Gd3+ was complexed with the DTPA
moieties on HA-PBA-DTPA. First, HA-PBA-DTPA (20 mg) was dissolved in 20 mL of 1:1
DMSO:H2O and titrated to pH 7 with 10% NaOH solution. Next, GdCl3 (10.0 mg, 0.038 mmol) was
dissolved in 5 mL of ultrapure water and added dropwise to the HA solution. The reaction was
then allowed to proceed for 24 h under constant stirring, and pH was periodically checked and
titrated to pH 7 with 10% NaOH or 10% HCl. Paramagnetic HA was purified by dialysis against
ultrapure water over 24-36 h (8 exchanges), and any remaining free Gd3+ was removed with PD10
desalting columns using ultrapure water as the mobile phase. Finally, the paramagnetic HA was
lyophilized and stored at -20 °C.
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Characterization of paramagnetic HA
The addition of DTPA to amphiphilic HA-PBA was confirmed through infrared spectroscopy,
using the procedure described by Moon et al.19 Modified and unmodified (control) samples of HA
powder were analyzed on a Perkin Elmer IR spectrometer. Gadolinium content of paramagnetic
HA was determined by spectrophotometric colorimetry and inductively coupled plasma mass
spectrometry (ICP-MS). The colorimetric assay was performed with a standard curve using
xylenol orange as an indicator of free gadolinium after reaction completion, using a previously
published protocol.39 Briefly, a standard curve of 15 µM xylenol orange in acetate buffer with a
concentration of gadolinium ranging from 10-100 µM was constructed. Unknown (experimental)
gadolinium concentration remaining after the reaction could then be determined through
spectrophotometry, and back calculated to obtain the molar content of gadolinium per gram of HA
conjugate. ICP-MS was used to confirm colorimetric measurements by first digesting the purified
paramagnetic HA product with nitric acid, then providing the sample to the UNMC nanomaterial
characterization core for ICP-MS analysis. The gadolinium content was then used to find the
molar content of gadolinium per gram of paramagnetic HA conjugate. After determining the
gadolinium content in the paramagnetic HA sample, T1-relaxivity experiments were performed on
a 7T/16cm Bruker PharmaScan (Bruker; Ettlingen, Germany) pre-clinical MRI scanner operating
on Paravision 5.1 software. Relaxivity image data were acquired using RAREVTR (Rapid
Acquisition with Relaxation Enhancement (RARE) with variable repetition time) sequence with ten
repetition (TR) times (10000, 5000, 3000, 1500, 1200, 800, 500, 450, 400, 300 ms) and an echo
time (TE) of 12.76 ms. Eleven slices (1 mm slice thickness) with image matrix size of 128 x 128
and field of view (FOV) of 30 mm x 30 mm were acquired for a total acquisition time of 9 min and
17 sec. T1 maps were generated using in-house developed computer program written in
Interactive Data Language (IDL; Exelis Visual Information Solutions; McLean, VA, USA). A range
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of concentrations of paramagnetic HA, measured by gadolinium concentration, were analyzed to
determine relaxivity.

Characterization of HA-derived nanoparticles
Nanoparticles were formed by self-assembly after dissolving the freeze-dried HA conjugates,
i.e. paramagnetic HA alone, fluorescent HA alone, or varying ratios of the paramagnetic and
fluorescent HA conjugates, in ultrapure water. Except for the experiments investigating the
formation of multimodal nanoparticles over time, nanoparticle samples were equilibrated for 4 h
and filtered through a 0.45 µm syringe filter prior to performing any measurements. Particle size,
polydispersity index (PDI), and zeta potential were determined using a Malvern ZetaSizer ZS90
(Malvern Instruments; Malvern, UK). Transmission electron microscope (TEM) images were
obtained using a FEI Tecnai G2 Spirit TEM (FEI; Hillsboro, Oregon) available in UNMC’s electron
microscopy core facility. Prior to TEM imaging, nanoparticles (concentration 1.0 mg/mL in
ultrapure water) were placed on a Formvar/Silicone monoxide coated 200 mesh copper grids and
allowed to adhere for approximately 2 minutes, Nanovan negative stain was applied for 30
seconds, and the sample blotted to remove excess solvent or material.

Formulation Optimization
The ratio of HA-Cy to HA-Gd was optimized by comparing the fluorescence intensity to
gadolinium content. Spectroscopic and imaging experiments were performed with a range of
formulations to determine the optimal optical properties for imaging. Briefly, a series of
nanoparticles with varying concentration of HA-Cy7.5 were prepared and characterized using a
UV-Vis spectrophotometer (Thermo Fisher Scientific; Waltham, MA), a Fluoromax fluorometer
(Horiba; Kyoto, Japan), a Pearl Trilogy small animal imaging system (LI-COR; Lincoln, NE) and
a custom made fluorescence image-guided surgery system (FIGSS), which previously described
elsewhere.40,41 The appropriate mass of paramagnetic HA needed to yield a concentration of 100
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µM Gd3+ (the clinically ideal concentration for imaging42) was prepared as a stock solution, and
varying concentration of HA-Cy7.5 was added to obtain a concentration ratio range from 0.8 to
80 Gd3+ ions to Cy7.5 molecules (referred to as Gd:Cy7.5 ratio hereon), and optical and magnetic
properties measured.

Cytotoxicity of SAMINs
Cytotoxicity was assessed using the CCK8 assay (Dojindo Molecular Technologies; Dojindo,
Japan). Non-malignant human breast (MCF10A) and vascular (HUVEC) cells were seeded onto
96-well plates at a seeding density of 25,000 cells/well. Imaging agent concentrations of 0.01,
0.05, and 0.10 mg/mL were incubated with the cells for 4, 24, and 48 h. Viability was measured
relative to untreated cells. After incubation with nanoparticle-containing media, cells were
incubated for 1-2 h with 10% CCK8 reagent in media according to the manufacturer’s instructions.
After incubation, the absorbance was measured at 450 nm using a Synergy HTX microplate
reader (BioTek Instruments, Inc.; Winooski, VT) and relative viability was calculated.

Preparation of Tissue Phantoms with Cell-Based Tumor Inclusions
Tissue phantoms were prepared using previously published16,27,43–45 and newly developed
methods. Bovine liver and porcine muscle samples were obtained from a local grocery store and
homogenized using a handheld homogenizing probe (VWR International; Radnor, PA). The
sample volumes were recorded, then the samples were frozen and lyophilized for later use.
Reconstituted phantoms were prepared by adding hemoglobin or tissue homogenate to gelatin
and water. MDA-MB-231 cells were cultured and incubated with multimodal nanoparticle
formulation for 12 h prior to imaging to simulate tumor uptake of SAMINs. Tumor-like inclusions
were prepared by suspending the cells at 30 million cells/mL in a 5% alginate in PBS solution.
Volumes of 5-50 µL of cell suspension were pipetted into a solution of 100 mM CaCl2 and allowed
to crosslink to form a spherical inclusion. Finally, the inclusions were placed in tissue phantom
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samples at different depths. Phantom samples were imaged with three imaging techniques
relevant to integrating MR and fluorescence imaging. First, fluorescent images were obtained
using a Pearl Trilogy Small Animal imaging system (LI-COR; Lincoln, NE) utilizing the 800 nm
excitation channel, then FIGS images were obtained using a 785 nm excitation source and
integrated NIR and visible optical channels. Finally, the phantoms were imaged on a Bruker 7T
pre-clinical MRI scanner (T1-weighted MRI parameters for T1 mapping were: TR/TE, 800/6.38 ms;
flip angle, 180°; field of view, 4 cm; slice thickness, 1.2mm; matrix, 128×128).

Mouse Model of Breast Cancer
All animal studies were performed in accordance to a protocol approved by the UNMC
Institutional Animal Care and Use Committee. Breast tumor xenografts were grown by injecting
(how many) MDA-MB-231 tumor cells subcutaneously into 12-week-old female athymic nude
mice (Jackson Laboratories; Bar Harbor, ME). When tumors were reached 500-1000 mm3, mice
were injected with contrast agent through intravenous infusion via a tail vein. Mice were dosed
with SAMINs optimized to 0.005 mmol/kg Gd3+ and 10 nmol Cy7.5. For the control group, mice
were dosed with 0.200 mmol/kg Magnevist. MRI scans of the mice were taken immediately prior
to injection, then at 2-, 4-, and 24-h time points. T1-weighted MRI parameters for T1 mapping were:
TR/TE, 800/6.38 ms; flip angle, 180°; field of view, 4 cm; slice thickness, 1.2mm; matrix, 128×128.
After the final MR image acquisition, the mice were euthanized and imaged using FIGSS to
simulate image-guided surgical removal of the malignancy. The mice were then dissected, and
organs removed to determine relative biodistribution studies as described below.

Relative Biodistribution of SAMINs
The relative biodistribution was characterized through fluorescence imaging and ICP-MS
analysis. After imaging, mice we necropsied to image vital organs and tumors with a LI-COR Pearl
Trilogy small animal NIR imaging system. Images were processed in ImageStudio software (LI-
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COR; Lincoln, NE). Organ samples were taken for each mouse and weighed, homogenized, and
then prepared for ICP-MS analysis by digesting the samples with 1:3 nitric acid in hydrochloric
acid solution. The ICP-MS biodistribution samples were then given to the UNMC nanomaterials
core facility for instrumental analysis. Biodistribution was calculated from gadolinium content in
the organ samples, and average organ weights for bone and muscle to calculate percent injected
dose accumulation were obtained from the Jackson Laboratories online Mouse Phenome
Database.

Results
Synthesis of Self-Assembled Multimodal Imaging Nanoparticles
SAMINs are comprised of two different types of modified HA: fluorescent HA and
paramagnetic HA. Each conjugate is synthesized separately, then the ratio of fluorescent HA to
paramagnetic HA is adjusted to reach optimal fluorescence and MR signal intensity as a contrast
agent for integrated imaging. Synthesis and characterization of the Cy7.5-modified amphiphilic
HA was performed as previously described.5,6 Amphiphilic paramagnetic HA was synthesized
as shown in Figure 3A. Figure 3B shows the structure of the fluorescent HA conjugate, HA-PBACy7.5. Synthesis of HA-PBA-DTPA was confirmed by the presence of additional O-H stretch peak
intensity and changes in the carbonyl peak, seen at 1500-1750 cm-1 in the infrared absorption
spectrum shown in Figure 3C. Synthesis of paramagnetic HA was confirmed by ICP-MS.
Relaxivity data of the SAMINs, shown in Figure 3D, demonstrated T1 relaxivity of 5.5 mM-1s-1,
which is comparable to that of Magnevist,42 a routinely used clinical MRI contrast agent.
Fluorescent HA retains bright NIR fluorescence in the multimodal formulation (Figure 4E).
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Figure 4: Synthesis of self-assembled multimodal imaging nanoparticles (SAMINs).

(A) DTPA dianhydride is reacted with hydrophobically modified HA to produce HA-PBADPTA followed by Gd3+ complexation to yield paramagnetic HA-PBA-GdDTPA. (B) HA-PBACy7.5 was synthesized as described in the corresponding text. (C) HA-PBA and HA-PBA-DTPA
were confirmed with IR spectroscopy by an increase in C=O and O-H stretch peak intensities. (D)
SAMIN relaxivity and (E) fluorescence were characterized and indicated the potential for magnetic
resonant and optical imaging.
Cy7.5-modified and gadolinium-modified amphiphilic HA conjugates and SAMINs result in
nanoparticles as indicated in Figure 5. The nanoparticles comprised of paramagnetic HA have a
smaller number average hydrodynamic, 69.57 nm with a PDI of 0.122, compared to HA-PBA-
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Cy7.5 or SAMINs. The HA-PBA-Cy7.5 nanoparticles had relatively higher number average
hydrodynamic diameter of 92.82 nm with a PDI of 0.285. The SAMINs were measured to have a
number average hydrodynamic diameter of 97.81 nm, with a PDI of 0.142. We expect that, due
to the dynamic nature of polymeric aggregate nanoparticles, the different HA conjugates
exchange between nanoparticles to form a homogeneous distribution of nanoparticles containing
both species of HA conjugates. The zeta potential also differed between, HA-PBA-Cy7.5
nanoparticles had the lowest zeta-potential (-12.3 mV), whereas paramagnetic HA nanoparticles
showed a zeta potential of -7.81 mV and SAMINs demonstrated a -8.37 mV.
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Figure 5: Physical characterization of
nanoparticles from amphiphilic HA.
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(A) HA-PBA-GdDTPA, (B) HA-PBA-Cy7.5, and (C) SAMINs. Histograms are dynamic light
scattering data and inset images are TEM images of the same nanoparticles. The scale bar
represents 100 nm.

Formulation Optimization
The sensitivity of MRI using gadolinium as a contrast agent is lower than the sensitivity of
fluorescence by several orders of magnitude,13 therefore the ratio of gadolinium to Cy7.5 in
SAMINs must be precisely tuned. Figure 6 reports the results of imaging agent Gd:Cy7.5 ratio
calibration in order to determine the optimal ratio for formulation for in vitro and in vivo studies.
Upon higher Cy7.5 content, self-quenching is observed. The optimal Gd(III):Cy7.5 ratio was found
to be 60 Gd(III):Cy7.5 molecules, as shown in Figure 6A and B. Examining the integrated
fluorescence intensities Figure 6B, the 60 Gd(III):Cy7.5 ratio was 20% brighter than the next
closest ratio (80 Gd(III):Cy7.5) and 460% brighter than the ratio at approximately 1:1
Gd(III):Cy7.5. These results are further demonstrated visually through images of the vials
containing the different formulations, and the 60 Gd:Cy7.5 sample shows the brightest
fluorescence as seen in Figure 6B and still maintaining consistent MR signal.
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Figure 6: Ratio optimization of SAMINs.

To achieve optimal contrast in both MR and fluorescent imaging modalities, the
concentration of Cy7.5 must be calibrated to the ideal concentration of gadolinium for MRI
contrast. (A) Fluorescence emission spectra of SAMINs with varying ratios of Gd:Cy7.5. The
maximum fluorescence intensity as a function of concentration is shown in (B), from which the
optimal ratio is derived. MR and NIR fluorescence images of the formulations are presented to
illustrate the process of optimizing the ratio of gadolinium to Cy7.5.
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Cytotoxicity of SAMINs and Components
Figure 7 shows the results of cell viability assays with two non-malignant cell lines over
three time points, demonstrating the SAMINs and both component HA derivatives are nontoxic at
concentrations of 0.01, 0.05, and 0.10 mg/mL of contrast agent. MCF10A and HUVEC cells were
chosen as cell lines to investigate if exposure to SAMINs resulted in any overall toxicity to
representative, non-malignant endothelial and epithelial cells, respectively. At a concentration of
0.10 mg/mL of contrast agent, HUVEC cells demonstrated 99.2% ± 21.4% viability with SAMINs,
97.0% ±26.8% viability with HA-Cy7.5, and 91.4% ±29.1% viability with HA-Gd. MCF10A cells
exhibited a lower standard deviation than the HUVEC cells, with 98.8% ±4.0% viability with
SAMINs, 98.4% ±4.2% viability with HA-Cy7.5, and 100.0% ±3.9% viability with HA-Gd when
treated with 0.10 mg/mL contrast agent.
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Figure 7: Cytotoxicity of SAMINs and individual components in two non-malignant cell lines.
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The relative viability of each component formulation: (A,B) HA-PBA-GdDTPA, (C,D) HAPBA- Cy7.5, (E,F) SAMINs was evaluated using a CCK8 cytotoxicity assay. The left column
(A,C,E) is data for HUVEC and the right column (B,D,F) is for MCF10A cells

Phantom Imaging Models
Figure 8 shows the results of fluorescence imaging using adipose, muscle, and liver tissue
phantoms. The images of the different samples were analyzed to evaluate the difference in
scattering and depth of detection of relevant tissue types with normalized signal intensities. Figure
8D-F show the change in overall signal intensity over the region of interest for each depth and
tissue type. The average fluorescence intensity per pixel was calculated to show differences in
intensity by tissue type. Adipose tissue phantoms demonstrated the highest fluorescence
intensity, due to less dense optical absorption. For example, 50 µL inclusions at 5 mm deep in
adipose were 60% brighter than muscle and 80% brighter than in the liver at the same depth. The
same pattern of signal intensities is uniformly observed for each depth for adipose, muscle, and
liver phantoms and is most apparent for the samples with 5 µL inclusions. Adipose tissue
phantoms demonstrated an average fluorescence intensity per pixel 18.5-fold greater for 5 µL
inclusion sample at 5 mm of deep in adipose compared to muscle; this size occlusion was only
detectable to 4 mm in the liver phantom. Figure 7G-I shows the results of calculating the scattering
vs. signal intensity at different depths and sized for the tissue phantoms, which follow a trend
inverse to that observed for mean fluorescence intensity per pixel. While the overall signal
obtained from samples with smaller inclusion volume is lower, the signal to scattering ratio is
higher. Furthermore, in samples with high optical density, a higher signal to scattering ratio was
observed. Liver tissue phantom samples showed the highest signal to scattering ratios, with the
5 µL inclusion at 2 mm showing a signal to scattering ratio of 12.64. Comparatively, the
corresponding muscle tissue phantom (SSR = 3.73) and the corresponding adipose tissue
phantom (SSR = 1.91) showed much lower SSR ratios.
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Figure 8: In vitro studies of depth detection and cellular uptake of SAMINs.

Fluorescence contrast in three different simulated tissue phantom models demonstrates
viability as a contrast agent in a variety of tissue types. Figure (A) shows the contrast fluorescence
image of tumor-like inclusions embedded into adipose tissue phantoms, which allows the depthdependent signal (D) and scattering (G) profiles to be characterized. Figure (B) shows the same
data for simulated muscle tissue phantoms, which demonstrate different depth-dependent signal
(E) and scattering (H) profiles. The fluorescence imaging data for liver tissue phantoms, for which
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depth-dependent signal (F) and scattering (I) profiles, differ remarkably from both adipose and
muscle tissue phantoms.

MRI-guided FIGS
Figure 9 shows the results of a proof-of-concept in vivo experiment using SAMINs to integrate
preoperative MR imaging with fluorescence IGS. A representative contrast-enhanced MR image
of a mouse bearing breast cancer xenografts is shown in Figure 9A-B. The signal and contrast
(relative to adjacent muscle) both increase due to the multimodal nanoparticles (Figure 9C-D),
where the R1 enhancement when normalized for dosage is found to significantly higher for the
SAMINs over Magnevist. While Magnevist may show higher change in R1, the SAMIN formulation
results in a better signal increase with a 40x lower dosage of gadolinium. After MR imaging, the
mouse was euthanized and underwent a mock surgical resection of the MR contrast-enhanced
tumor using fluorescence contrast-enhanced IGS. Representative fluorescence images are
shown in Figure 9E-H. The IGS system utilizes a hand-held spectroscopic “pen” that uses a laser
for excitation. When the pen excites tissue just off the tumor (Figure 9E), no contrastenhancement is observed in the wide-field surgical imaging display. When the pen is moved onto
the tumor, strong NIR signal due to Cy7.5 is observed in the NIR channel of the IGS system,
pseudo-colored cyan and overlaid onto the visible light channel of the system (Figure 8F). The
tumor was then resected using fluorescence image-guidance. Figure 9F shows that the tumor
was causing the fluorescence emission, while the connecting muscle adjacent to the xenograft
resulted in background levels of fluorescence (Figure 9H). Inset images in Figure 9G-H report the
NIR spectroscopic signal from Cy7.5 contained in the SAMINs and correspond to the MR signal
and fluorescence IGS.
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Figure 9: Integrated preoperative magnetic resonance imaging with intraoperative fluorescence
image-guided surgery using a breast cancer xenograft model.
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(A) Pre-injection image of mouse bearing breast cancer xenograft tumor. (B) Region of interest
(tumor) 24 h after IV injection of SAMINs (0.005 mmol/kg Gd3+; 0.5 µmol/kg Cy7.5). (C) Change
in relaxivity (R1) and change in R1 normalized to injected dose (D) after injection with Magnevist
or SAMINS (for SAMINS, N=6; for Magnevist, N=3). (E-H) Fluorescence-guided surgery using
SAMINs. (E) Excitation of tissue away from tumor indicates minimal signal, whereas (F) excitation
of tumor shows strong NIR fluorescence signal due to SAMIN deposition in tumor. (G) Removed
tumor was confirmed and the source of contrast enhancement, while (H) shows that excitation of
area from which the tumor removed is no longer fluorescent. The insets in G, H show the NIR
spectral response when the laser is direct on and off the contrast-enhanced areas, respectively.

Biodistribution of SAMINs
Figure 10 reports the biodistribution of the SAMINs with Magnevist as a control. Percent
injected dose of gadolinium was obtained via ICP-MS analysis of organ samples as shown in
Figure 10A. Only the liver and pancreas show insignificant differences between the SAMINs and
Magnevist, while significant difference is observed in all other organs of interest. Where SAMINs
yielded a 3.30% injected dose of gadolinium accumulation in the tumor, the Magnevist showed
only 0.80% accumulation in the tumor. Furthermore, the SAMIN formulation lead to lower
accumulation of gadolinium in the muscle tissue than Magnevist, resulting in higher tumor-muscle
contrast as also demonstrated in Figure 9A. Figure 10B-C confirm that NIR signal is consistent
with the presence of tumor (iRFP fluorescence in Figure 10C) and clearance organs.
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Figure 10: Biodistribution of multimodal imaging agents.
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(A) Comparative biodistribution of gadolinium when dosed as SAMINs vs. Magnevist. (B) Relative
distribution of SAMINs as indicated NIR fluorescence signal indicates increased in signal intensity
tumor (confirmed by iRFP expression from the MDA-MB-231 cells in (C)) and clearance organs.

Discussion
We demonstrated the use of self-assembled multimodal imaging nanoparticles (SAMINs) to
integrate preoperative MR imaging with fluorescence image-guided surgery. We successfully
synthesized new contrast agents, which provide both fluorescence and MR signal in vivo and in
vitro. Using a mixed micelle formulation provides a convenient and reproducible method to
optimize the ratio of MR to fluorescence component in a nanoparticle formulation.
The synthesis of paramagnetic HA introduced new considerations in formulation. Prior work
with gadolinium-modified HA has only used HA as a macromolecular scaffold rather than an
amphiphile, 38,46 where the polymers do not self-assemble into nanoparticles. In this work, as well
as our prior work with HA-based imaging16,17,27 and drug delivery agents,34 we modify HA with
hydrophobic moieties (specifically PBA) to drive self-assembly into nanoparticles. However, the
addition of gadolinium was found to increase hydrophobicity, requiring the percent weight
composition of hydrophobic PBA to be lower on paramagnetic HA than on fluorescent HA. One
of the distinct advantages of using a mixed micelle formulation, as opposed to adding both
gadolinium and Cy7.5 to the same strand, was the ability to calibrate the hydrophobicity of the HA
derivatives. Previous work by others47,48 has demonstrated the use of dual-functionalized
polymeric contrast agents, but in such formulations the ability to calibrate contrast agent ratio or
hydrophobicity is much less apparent.
Prior to moving into more in-depth studies, the cytotoxicity of the SAMINs needed to be
assessed. In our studies, each component was tested individually to ensure that the HA-PBACy7.5 and HA-PBA-GdDTPA mixed micelle components were cytotoxic, and then the multimodal
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formulation was tested as well. Gadolinium ions, when not bound to a chelating ligand such as
DTPA, are known to be highly toxic and therefore any agent bearing gadolinium must be shown
to be nontoxic at therapeutic dosage.13,42 Many other formulations based on inorganic
nanoparticles suffer from toxicity concerns,13 and while iron oxide nanoparticles have recently
emerged as a strategy for MR contrast and are less toxic, iron oxide-based agents are primarily
used for T2 contrast.49 In our experiments, the gadolinium-bearing HA conjugates are shown to
have low cytotoxicity while maintaining high T1 contrast, an advantage over other inorganic MR
contrast agents.
When evaluating the efficacy of experimental contrast agents, sample to sample variation
can be difficult to minimize.31 Cell assays help to characterize uptake in a more controlled manner
but are limited in scope. As shown by our lab27 and others,31,44,45,50,51 the use of tissue mimicking
phantoms can help to characterize optical properties and potential for contrast in a highly
reproducible manner. Developing these models for different tissues aids in simulating the
biological conditions observed in vivo. In this work, we expand our use of simulated tissue
phantoms to model liver and muscle tissue and demonstrate the use of cell-based inclusions to
model tumors. While the tumor microenvironment is difficult to model, the use of cell-based
inclusions demonstrates the possible outcome of imaging in vivo using the same cancer cell lines
and provides an insightful step of imaging agent evaluation prior to further in vivo studies.
In addition to characterizing uptake and overall signal, the use of tissue-mimicking phantoms,
allows investigation into the ability to detect tumors that may be small or located deeper within
tissue. Furthermore, many cancers metastasize to different organs and tissues throughout the
body, which have inherently different optical profiles. Fluorescence imaging has limitations due to
depth and difference in scattering profiles based on the organ, and the use of tissue phantoms
allows characterization of these effects in a controlled manner. Higher scattering is likely a
function of the increased content of contrast agent, resulting in higher signal in all directions, and
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therefore scattering through the phantom media. The insights gained from these experiments
helps to predict the signal intensity that will be obtained from in vivo samples, ultimately guiding
the design of new contrast agents.
After validation in tissue phantom models, we performed a pilot study to analyze the efficacy
of our contrast agents in a mouse model of breast cancer. The use of polymeric agents for
gadolinium delivery remains difficult due to the concentration of gadolinium needed to deliver high
contrast. A limiting factor in the dosage of macromolecular gadolinium-bearing contrast agents is
the overall mass of sample required to achieve adequate gadolinium concentration.52–54 Since the
mass percent of gadolinium in these contrast agents is relatively low, dosing is a unique challenge
as opposed to other contrast agents such as inorganic nanoparticles or small molecule contrast
agents. However, our results concur with previously published data38,46,55–57 for the use of
macromolecular contrast agents, in which MR signal is shown to increase and provide adequate
contrast in vivo. The contrast obtained in MR imaging is shown to increase over a 24-hour period,
which is also consistent with our previously published data5 on the biodistribution and optimal
imaging time for fluorescent HA in IGS.
After preoperative MRI, the fluorescence imaging performed with IGS shows high contrast in
the tumors. When compared to the muscle tissue, the tumor demonstrates much higher signal
than the muscle. While inorganic multimodal nanoparticle contrast agents have been shown to be
effective for both fluorescence and MR imaging,58–62 the reduced cytotoxicity of our formulation
and the easily calibrated contrast agent ratio provide key advantages over the existing technology.
Other groups have used polymers such as poly(ethylene glycol),57,63,64 however the use of
naturally occurring biopolymers such as hyaluronic acid is gaining prevalence65–67 of use in
nanomedicine for better biocompatibility68 and targeting.65 The enhanced targeting for certain
tumors achieved through the use of hyaluronic acid as the backbone for our contrast agents
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ensures specific uptake, resulting in higher contrast, as demonstrated in the ex vivo fluorescence
imaging of the organs.
The conclusions drawn from the in vivo imaging using the SAMINs are confirmed through
biodistribution studies with ICP-MS. We have previously reported on the biodistribution of Cy7.5labeled HA versus free Cy7.5,16,17 and the results obtained from gadolinium biodistribution concur
with the previous observations of increased tumor accumulation and higher tumor-muscle
contrast. Although the dosage of gadolinium was 40 times less (0.005 mmol/kg) than the dosage
of gadolinium with Magnevist (0.200 mmol/kg), the tumor-muscle contrast obtained using the
SAMIN formulation was much higher and will result in better imaging capabilities. The SAMIN
formulation also resulted in higher uptake in the spleen, consistent with primarily hepatic
clearance, while Magnevist showed higher accumulation in the kidney, exhibiting renal clearance.
Improving the contrast between healthy, non-cancerous tissue and malignant tissue remains
the top priority for research in image-guided surgery, including when evaluating preoperative
procedures. In this work, we have developed a nanoparticle formulation capable of providing
contrast for both MRI and FIGS, aimed at improving surgical guidance. Further work will aim at
increasing the MR signal obtained from the nanoparticles, as the current mass of paramagnetic
polymeric conjugate required to achieve sufficient contrast is a limitation to increasing the dosage.
In conclusion, this work is a starting point for the development of improved contrast agents to
leverage the targetability, improved biodistribution, and biocompatibility of polymeric
nanomedicine with the versatility of MRI and the sensitivity of FIGS.
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Chapter 3: Conclusion
As the importance of biomedical imaging in cancer treatment continues to
increase, state-of-the-art contrast agents will be required not only to leverage new imaging
equipment but to improve treatment outcomes.6,69 Preoperative imaging is ubiquitous in
surgical oncology, and as new instruments and better tools become available,
intraoperative imaging will permeate the field as well.6,70–72
The field of nanotechnology offers great promise in the design and development
of new contrast agents for the various instrumentation currently available.5,14,16 Numerous
new agents are under investigation, and in the present study, we used nanoscale
approaches to enable a combination of different moieties for signal in MRI and
fluorescence imaging.24,73 As new developments are made in the design, production, and
administration of nanoscale contrast agents, more options will be available to physicians
for both preoperative and intraoperative imaging.70,74

Evolution of multimodal contrast agents
The first generation of SAMINs was based on amphiphilic hyaluronic acid, which
enabled a mixed micelle formulation constituting both paramagnetic and fluorescent HA.
This first attempt at multimodality imaging incorporated MRI as the preoperative imaging
modality. Of the benefits offered by the SAMIN formulation, the most important were that
of extended circulation time when compared to Magnevist and the ability to tune the ratio
of fluorescent to paramagnetic agent. When compared to Magnevist, higher contrast was
observed at a lower concentration of gadolinium in the sample, with 40 times less
gadolinium needed for imaging.
The key limitation of this first-generation SAMIN formulation was in the mass
dosage required to achieve adequate signal. As with most polymer-based formulations,
most of the mass in a sample of SAMIN formulation was hyaluronic acid, not contrast
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agent, which lead to a relatively high mass for injection when compared to Magnevist.
With a weight percent of only 1% gadolinium, a total mass of 0.2 mg was needed to obtain
any signal in the region of interest. In preparing a sample for injection, the high mass of
sample resulted in a hydrogel, rather than liquid, formulation. Furthermore, increasing the
concentration of gadolinium through increasing the mass of injection, would not be
possible since a dose of 2mg/kg was already required.
The difficulty in formulation of SAMINs requires new directions in approach to
hydrophobic modification and imaging modality used. First, the inherent insensitivity of
MRI as an imaging technique proved to be a difficult barrier to overcome, and since other
techniques (especially radioactive techniques) offer higher sensitivity, alternative
approaches should be considered.12,13 Furthermore, hydrophobic modification increases
the mass and decreases the solubility of a given polymer, and as such contributed to the
problem of formulation.75,76 In the next generation of SAMINs, both shortfalls should be
addressed.

Rationale for next-generation probes
Surgical intervention remains the only cancer treatment with curative potential.3,5
Maximizing surgical efficacy therefore presents an opportunity for highly impactful
research.77 This project detailed the development of new multimodal contrast agents that
showed translational potential, but further optimization is required. Increasing the
concentration of contrast agent in the region of interest (the tumor) holds promise to further
improve translational viability.78
One way to improve accumulation in the tumor is through active targeting
strategies.13,79 Studies have been conducted to examine the possibility of adding
antibodies, peptides, and targeting ligands to nanoformulations.80–83 The approach of
adding a targeting moiety has been shown to increase tumor accumulation in some cases,
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especially in cancer where various biomarkers may be overexpressed.84–87 Realizing this
strategy, one possible way to improve the SAMIN formulation would be to include a
targeting moiety specifically targeting malignant cells.
As presented in the introduction, hyaluronic acid is already used as a targeting
ligand for the cell surface receptor CD44, which is overexpressed on many cancer
phenotypes.28,88 In recent studies conducted in our lab, HA was modified to decrease
binding affinity for CD44.89 Changing the CD44 binding affinity facilitates targeting
receptors other than CD44 in other forms of cancer; using retargeting strategies, future
generations of SAMIN probes could be applied to new clinical needs.

Second-generation HA-based multimodal probes

Building on the prior findings in Chapter 2 and out experiences with HA-based
probes, a new generation of HA-based multimodal contrast agents is under investigation.
The key limitation of the first-generation SAMINs was the low dosage of gadolinium
possible due to the relative mass ratio of gadolinium to HA. However, despite low signal
in MR imaging, high fluorescence signal was obtained in accord with our previous findings.
16,17

To remedy the low signal obtained preoperatively, an alternate imaging technique
is required. Position emission tomography was chosen as the preoperative imaging
technique for the development of second-generation SAMINs. As a radiographic imaging
technique, PET offers higher signal with a lower mass of contrast agent. As detailed in
Chapter 1, PET provides contrast via radioactive isotopes such as fluorine. In this
preliminary study, we used copper as a stand-in radiolabel due to the longer half-life and
more suitable working conditions for early-stage development.
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Figure 11: Overview of HA-based conjugates used for integrated PET and fluorescence
imaging.
The change in contrast agent required the use of different chelating agents for
copper than was used in the first generation of SAMINs. While DTPA was appropriate for
use with gadolinium, the macrocyclic chelates NODA and DOTA were better choices for
copper chelation. We present three different macromolecular species of hyaluronic acid
modified with DOTA and NODA, along with the use Cy7.5 or IR800 infrared dyes as
contrast agents for fluorescence imaging. Figure 11 presents a graphical overview of the
new contrast agents developed.

Results
Synthesis was confirmed through NMR. The signature peaks for the HA backbone
are shown for both sets of conjugates. Figure 12 shows the NMR spectra for NIR-modified
HA, and Figure 13 showed the NMR spectra for HA modified with chelating agents.
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Figure 12: NMR spectra of NIR dye-modified HA.
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Figure 13: NMR Spectra of chelate-modified HA.
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Further physical characterization was performed using size-exclusion chromatography
and inductively coupled mass spectrometry. The results from these experiments are
summarized in Table 3.
Conjugate

Agent
Molar Mass
(Mw)

HA-DOTA
HA-NOTA
HA-PEG-DOTA
HA-Cy-DOTA
HA-Cy-NOTA
HA-Cy-PEG-DOTA

16810
17210
18680
17150
17100
18880

Dispersity
1.29
1.28
1.33
1.34
1.34
1.35

Content, ug Cu/mg
polymer
47.12
21.21
40.86
27.23
18.32
25.65

Copper content,
umol Cu/mg
conjugate
0.74
0.33
0.64
0.43
0.29
0.40

Copper ions
per chain
12.46
5.74
12.01
7.35
4.93
7.62

Table 3: Summary data for the multimodal HA-based contrast agents.

Dye dontent,
umol dye/mg
conj.

Dye
molecules
per chain

-

-

0.145
0.145
0.145

2.5
2.5
2.5

Discussion
The NMR spectra confirm the synthesis of both NIR-HA species and all three
chelate-HA species. The spectra for polymers containing both NIR dye and chelating
agent are not presented due to the complexity of the spectra; interpretation is difficult due
to numerous overlapping peaks. Since the synthesis of each contrast agent is confirmed
individually, the synthesis of multimodal agents was subsequently confirmed through ICPMS analysis.
Using the data from SEC and ICP-MS, the starting dose of contrast agent could
be determined, requiring significantly lower mass than the first generation SAMINs
developed in Chapter 2. While time did not allow for full characterization of IR800-labeled
multimodal agents, similar results are expected in the continuation of the project.

Conclusion
In this conclusion chapter, the initial development of next-generation SAMINs is
presented. Building upon the observations in Chapter 2, the mass of contrast agent
needed to produce signal is greatly reduced due to the use of PET as the preoperative
imaging technique of choice. Furthermore, the transition from a self-assembled
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formulation with hydrophobic modification of HA to a macromolecular agent that likely
does not self-assemble further reduces the complexity of formulation. These new HAbased contrast agents provide an improvement over the previous SAMINs in the potential
for higher signal (and therefore contrast) with a lower mass of injected contrast agent.
Ultimately, improving the outcome of surgical intervention in cancer therapy
through both preoperative and intraoperative imaging holds promise to reduce mortality in
one of the greatest threats in modern medicine. In this project, the contrast agents
developed showed improved signal over conventional contrast agents, and furthermore
the ability to use multiple imaging techniques preoperatively and intraoperatively offers
significant advantage over convention methods.

Supplementary Methods
DTPA, N-hydroxysuccinimide, sodium phosphate, sodium azide, EDC, and copper
(II) chloride, were purchased from Sigma-Aldrich (St. Louis, MO). NODA, DOTA, and
DOTA-PEG were purchased from CheMatech (Dijon, France). DMSO was purchased
from Fisher Scientific (Pittsburgh, PA). Ethanol was purchased from UNMC internal
supply. Sodium hyaluronate (HA) was purchased from Lifecore Biomedical (Chaska, MN).
IR800 and Cy7.5-amine were purchased from Lumiprobe Corporation (Hallandale Beach,
FL).
NODA-HA and DOTA-PEG-HA were synthesized through NHS/EDC chemistry.
Briefly, 20 mg of hyaluronic acid (10 kDa) was dissolved in 30 mL of ultrapure water along
with 8mg of NHS and 8 mg of EDC. The mixture was allowed to react for approximately
30 minutes prior to the addition of chelate to allow for activation of the carboxylate groups.
Next, 5 mg of chelate in water was added dropwise to the mixture, and the reaction was
allowed to proceed for 24 hours. Samples were then removed and dialyzed against
ultrapure water for 48 hours under constant stirring. Samples were then frozen,
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lyophilized, and stored for analysis. This process has been used extensively in our
group.17,27,34
DOTA-HA was prepared from the DOTA anhydride reagent through dianhydride
hydrolysis as previously reported.38 Hyaluronic acid (20 mg, 10kDa) was dissolved in dry
DMSO for 24 hours prior to the dropwise addition of 5 mg of DOTA-GA in dry DMSO. The
reaction was allowed to proceed for 8 hours, then removed for dialysis against ultrapure
water for 48 hours. The sample was then frozen, lyophilized, and stored for analysis.
To obtain multimodal conjugates, infrared dye must be conjugated to HA prior to
the addition of chelating agent. Cy7.5-HA and IR800-HA were synthesized through
procedures previously published

. Briefly, dye was conjugated to HA through

16,90

NHS/EDC chemistry by combining HA (20 mg, 10 kDa) with 8 mg of NHS and 8 mg of
EDC in 30 mL of 1:1 ultrapure water and DMSO and allowing the activation of the
carboxylate groups for approximately 30 minutes. Dye solution in DMSO (1.0mg/mL) was
then added dropwise to the reaction mixture and allowed to proceed for 24 hours. The
sample was then removed and dialyzed against ultrapure water for 48 hours. After dialysis,
the sample was frozen and lyophilized for future use. The NIR-modified HA could then be
used as starting material for the addition of chelating agents using the same procedures
described above.
Initial characterization and confirmation of synthesis was performed using NMR.
For analysis, 3.0 mg of sample was dissolved in 600 µL of 1:1 d6-DMSO:D2O and NMR
was performed on a Bruker 500 MHz NMR spectrometer (Bruker Corporation, Billerica,
MA) . Spectra were analyzed in MNova software (Mestrelab, Santiago de Compostela,
Spain).
Gel permeation chromatography was performed on samples of concentration 4.00
mg/mL using a Water 1515 HPLC pump connected to Waters Ultrahydrogel 1000 and 250
columns (Waters Corporation, Milford, MA). The detectors used were a Waters 2410
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photodiode array detector, Waters 410 refractive index detector, and Wyatt MiniDawn
TREOS light scattering detector (Wyatt Technology Corporation, Santa Barbara, CA).
Samples were analyzed with an injection volume of 100 µL, a run time of 60 minutes and
flow rate of 0.45 mL/min in sodium phosphate buffer as the mobile phase (0.1M NaH2PO4,
3.85mM NaN3).
Copper content was determined by first degrading 5mg of sample in aqua regia (a
solution of 1:3 nitric acid to hydrochloric acid). 5 mg of sample was placed into a 10 mL
volumetric flask, to which 5 mL of aqua regia was added. Samples were heated and stirred
on a hotplate for 15 minutes at 50 °C. To account for evaporation, samples were then
diluted to the calibration mark on the volumetric flask. Samples were aliquoted into 1 mL
vials and provided to the UNMC Nanotechnology Characterization Core for ICP-MS
analysis.
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Chapter 4: Introduction
Designing a better multimodal contrast agent
In the first part of this dissertation, the development of a multimodal fluorescenceMR imaging agent was presented. However, limitations were observed due to the physical
composition of the nanoformulation. Questions around the optimization and improvement
of this construct stem from the limitations discussed in Chapter 3. A new formulation is
presented as a future direction for the platform using PET instead of MR imaging, an
improvement to the platform based on the observations of first-generation SAMINs. In this
chapter, we present the use of theoretical approaches to better understand HA-based
nanomaterials and use approach the design of new HA-based materials from a rational
design process.
HA-based materials are not uncommon in drug delivery systems, with applications
ranging from a backbone or scaffold as we and others have presented27,131–133 to use as a
targeting ligand for other nanoparticulate materials.38,134–137 The procedures and outlook
for using hyaluronic acid or other polysaccharides are more arduous than with synthetic
polymers, however naturally occurring polymers such as HA bring benefits such as better
biocompatibility.136,138–141 A detailed design process for HA-based nanomaterials still
requires more research and standardization, but the body of work to follow attempts to
contribute to that end goal.140
Evolution in the treatment and diagnosis of complicated diseases, such as cancer,
has prompted the investigation of more advanced drug or imaging agent formulations to
improve prognosis and reduce comorbidity.21,91–93 As the cost and development time
required for new drugs to reach clinical use continues to increase, the field of
nanomedicine has emerged as a promising area of research in an attempt to substantially
improve therapeutic outcome, particularly in cancer chemotherapy.94–97 The range
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materials available to create drug delivery systems includes soft matter, such as polymers
and lipids, and solid materials like silicon, gold, or iron colloidal nanoparticles.98–100 Each
different structural approach brings benefits and drawbacks, and the choice of material
largely depends on the application and desired effect.101 Nanoformulations, such as
micelles, liposomes, and hydrogels, have gained popularity as a step toward these
goals.91,102 Self-assembled polymeric nanoparticles are particularly attractive as drug
delivery platforms due to the low cytotoxicity of the components, highly tuned structures,
and increased accumulation in disease sites.21,103–105 Among self-assembled polymeric
nanoformulations, naturally occurring polymers, including hyaluronic acid, heparin, and
chitosan are widely-used for formulation due to innate biocompatibility and ease of
chemical modification when compared to peptides or nucleic acids.65,67,106–108
While the number nanomedicine publications have continued to rise, very few of
these inventions make it to market.109,110 This problem is exacerbated by the lack of
meaningful methods to determine the efficacy and efficiency of a given formulation;
comparing one nanomedicine to another or even objectively describing how well the
nanomedicine treats a given disease is nearly impossible.93,111 Furthermore, choosing an
ideal drug carrier vehicle is difficult and there are very few established design processes
for the development of new nanoformulations, which has resulted in calls from
government, industry, and academic institutions for increased development in design
processes.112–117 To overcome the challenges preventing successful clinical adoption, and
to further integrate nanoformulation into the industrial research and development process,
quantitative, standardized methods of evaluating and designing nanomedicine must be
developed.118–121
When designing a drug delivery system at the earliest stages, consideration must
be given to several key factors that will dictate efficacy as a nanomedicine, including: how
the drug or imaging agent will be formulated into the nanoparticle,122 how the delivery
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system will act when administered to cells or in vivo,23,91,123 and pharmacokinetic factors
such as release kinetics and particle decomposition.86,124 Frequently, controlled release
and targeted delivery are goals of using a nanoformulation and these outcomes can be
influenced or designed through mathematical or computation methods.125 Furthermore,
therapeutic agent formulation through loading into nanoparticles can be accomplished by
many means, including covalent attachment
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and physical entrapment,34,126 each

requiring different approaches to drug and delivery system compatibility design.
Ultimately, the supramolecular or colloidal behavior of a drug delivery system is
derived from its constituent components.127 In polymer-based delivery systems, the
dynamics of inter-particle exchange and the number of polymer chains per particle are a
direct result of chemical composition of individual polymer chains.128,129 The design and
characterization of these materials can also incorporate strategies for environmentally
responsive systems, using factors such as redox potential or pH for controlled release of
drugs or specific functions when inside the cell.130 Working toward a better understanding
of the most fundamental properties and chemical interactions in drug delivery systems will
ultimately lead to better drug formulations and patient outcomes.93

Polymeric Drug Delivery Systems
The choice of material for a new drug delivery is a design consideration that
depends on many factors, such as biocompatibility, production ability, uniformity in
formulation, and suitability for a given application.142 Polymeric systems are a popular
choice in drug formulation because of the high degree of customization and historic usage
of polymers as excipients.143,144 Similarly, liposomal formulations have been demonstrated
to be of clinical relevance with the approval of Doxil, a liposomal formulation of
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Doxorubicin.145 The increase of interest in nanoformulations has resulted in greater need
for deeper understanding of polymeric systems and the design of new nanomedicines.96
Although polymeric components have been widely used as excipients for decades,
the use of self-assembled or macromolecular therapeutic agents incorporating polymers
is a more recent development. As a greater understanding of pharmacokinetics has been

Figure 14: Physical size scale of several classes of polymeric therapeutic agents.
Reproduced with permission.146
developed in recent decades, the use of macromolecular components in formulation has
emerged as a way to alter the pharmacokinetic and pharmacodynamic profiles of
therapeutic agents.103 demonstrates the relative size of polymeric systems used for
delivery of therapeutics.146
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Nanoformulation Component Selection
With the rapid increase in nanomedicine publications, the components under
investigation for drug delivery systems has also expanded.110,147,148 Choosing a polymer
on which to base a new nanoformulation requires consideration of different factors
depending on the target application. Among the most important factors to consider when
developing a drug delivery system are biocompatibility, targeting, and compatibility with
the therapeutic agent of choice.23
One of the most promising attributes of nanomedicine is the ability to co-formulate
drugs and/or imaging agents, giving rise to synergistic co-formulations or theranostic
nanomedicines.149–151 However, the innate difficulty of combining two agents, while
maintaining colloidal stability and loading efficiency, is an obstacle to effective translation.
Most modern chemotherapy treatment regimens involve the use of multiple drugs and
leveraging the innate advantage of nanoformulation to co-formulate different agents in
different ratios is an important goal in achieving clinical adoption.141 Developing
quantitative methods to investigate co-formulation potential of therapeutic or imaging
agents will accelerate the development of next-generation nanomedicines and theranostic
treatments.98,152
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Molecular Design in Polymeric Systems for Nanomedicine
Molecular design is the process of designing a molecule or molecular system to
achieve specific physicochemical properties.153–156 Most often associated with drug
design, the process of using quantitative descriptors to best select or design a new
molecular entity is not new.157 The application of such methods has more recently been
applied to the components of drug delivery systems, particularly to better inform the
development of nanomedicines.158 As shown in Figure 15, nanoparticle therapeutics
present multiple opportunities for design of components with specific interactions or
physical properties.

Figure 15: Important factors in the design of new nanoformulations. Reproduced with
permission.125
The most important decision made when designing a new formulation is the
material and platform from which to build the new formulation. Whether starting with soft
or hard particles or aggregates, the same design considerations apply when looking at the
biological corona and other interface properties of the nanoparticle.159,160 Adsorption of
serum proteins dramatically affects the ultimate pharmacodynamic fate of a nanocarrier,
and the composition of the protein corona depends heavily on the composition and surface
properties of the nanoparticle.161–163 Due to the importance of the protein corona, recent
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effort has been made to optimize or design the surface properties of nanoformulations to
affect desired in vivo behavior.164–166
Commonly, new nanomedicines are evaluated solely based on the comparative
efficacy between the new formulation and the free drug, which often does not accurately
reflect the translational relevance of the new formulation.95 While most publications
presenting a new nanoformulation report physical attributes such as the size, shape, and
charge of the particle, most reports would benefit significantly from increased investigation
into the fundamental physicochemical properties of the nanomedicine, such as
interactions between the drug and its carrier, the surrounding environment, or serum
components.167–169 In contrast to small-molecule drugs and biological therapeutics,
nanomedicines requires a different perspective from which to predict quantitative
structure-property relationships, pharmacokinetic profiles, formulation stability and release
kinetics. Recently, computational methods to predict the physicochemical properties of
nanomedicines have been reported as approaches to expedite formulation optimization
and have shown potential to produce more efficacious nanomedicines, but there are no
complete or redistributable tools for such investigations.125,170–173

Molecular Modeling of Polymeric Systems
The use of mathematical or computational means to expedite and optimize the
drug delivery system design process have emerged as promising starting points.125,174–177
Theoretical approaches include the use of methods ranging from group contribution or
QSAR studies125,153,154,177,178 to simulation methods such as Monte Carlo simulation or
molecular dynamics simulation.174,179–181 While modeling a full-sized drug delivery system
at an all-atom or united-atom level remains impractical in most cases, investigations of
components or interactions among components has shown value in preclinical
studies.167,173,182–184
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Computational chemistry has had significant impact in nearly every aspect of
chemical research, ranging from materials and paint to drug design and artificial
intelligence.185–187 However, A deeper theoretical understanding is needed to improve the
design of nanomedicines.188 To date, very few practical paradigms for the empirical design
of new formulations exist, and improving the tools available through computational
methods could decrease the development time and cost for new formulations.79,125,177,189
Foundational to the ability to design high-capacity formulations is a deep understanding
of the fundamental physicochemical properties of existing high-capacity formulations.154
By further investigating and defining the behavior of high-capacity formulations
computationally, the insights obtained can be applied to other model systems and
ultimately used as a design criterion for new nanomedicines to improve the outlook for
clinical translation.155,190

Types and usage of simulation
The many tools and programs available for simulation of molecular systems are
most intuitively divided into the scale of systems that can be modeled. With larger systems
and greater detail, the demands on computational resources increases a tradeoff which
requires consideration when beginning a computational study.179 However, as more
powerful supercomputers are developed and more efficient simulation methods are

Figure 16: Overview of appropriate computational simulation methods at various scales.
Reproduced with permission 179.
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introduced, the size and level of detail achievable continues to improve over time.191,192 To
model large systems, especially those of larger than 50 nanometers in size, resolution
must be sacrificed to reduce computational resource usage to reasonable levels.193 Figure
16 presents an overview of the size and appropriate methods for the different classes of
simulation.179
Quantum mechanical (QM) calculations rely on the Schrodinger equation to model
the electronic structure of a molecule of interest. However, due to the high computational
resource requirements to perform QM calculations, the use of such programs is limited to
only a few angstroms in most cases.194,195 The high precision offered by electronic
structure calculations introduce the ability to predict numerous physicochemical
properties, including NMR and optical spectra, solubility, and structural conformations and
reactions.196,197
Moving to larger systems, molecular dynamics simulation offers the ability to
simulate a greater number of atoms at the expense of resolution by using a “ball and
spring” model and Newtonian mechanics.198,199 Such systems are more relevant to drug
delivery systems because polymers and proteins can be simulated, whereas with QM
methods, such large numbers of atoms are impractical to simulate.194 Furthermore, the
approach of using Newtonian mechanics to describe the interactions between atoms can
be extended to coarse-grained techniques, in which groups of atoms are treated as a
single unit.171,179,200

Correlation between experiments and simulation
Theoretical investigations of physicochemical systems are only useful in the case
that the simulations accurately model phenomena as observed experimentally.98,201 Any
effort to incorporate computational simulation into research strategy necessitates
validation.168,202 Validation of simulation results should be performed using experimental
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Figure 17: Experimental methods in correlation with computational simulations.
Reproduced with permission.241
techniques appropriate to the system under investigation, which can vary widely
depending on methodology and the molecular system of interest.203
When developing a new macromolecular or self-assembled polymeric formulation
using computational methods, the ability to relate predicted or theoretical properties to
experimental results is paramount. Molecular modeling only proves useful when natural
phenomena are accurately reproduced. In Figure 17 molecular modeling methods are
represented as square boxes to indicate the appropriate size and time scales attainable
with each method. The rounded sections indicate possible experimental methods to be
used at a given time and size scale. Most of the experimental techniques available to
characterize a polymeric assembly are derived from polymer science in that techniques
such as small angle scattering (SANS, SAXS) and refractometry have long been used to
study the dynamics of polymer strands.125,204,205 Furthermore, light scattering techniques
such as dynamic light scattering and static light scattering can also provide insight into the
supramolecular structure.206–208
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Stemming from the extensive methods developed in polymer and colloidal
chemistry, characterization of nanomedicine is often dependent on the components of the
macromolecular system.23,33,209 Additionally, computational modeling of polysaccharides
presents challenges due to charge, ring systems, or complex geometries, which are not
present in many synthetic polymers such as poly(ethylene glycol).210,211 Of the most
important methods to note are scattering methods, which use laser light or particles (such
as X-rays) to characterize macromolecules.171,212,213 In the following chapter, dynamic light
scattering is chosen to physically characterize the molecular assemblies under
investigation, which offers the ability to determine the size of aggregates formed in
solutions of amphiphilic hyaluronic acid.214
Characterization of nanomedicine components plays a major role in the research
and development of new formulations.103,215 Maintaining strict control over particle size,
composition, and stability is required of any therapeutic agents with potential use in the
clinic.111 As research efforts continue to grow around the use of macromolecules in drug
delivery systems, new methods for characterization, analysis, and quality control of
nanomedicines will be increasingly valuable.216 The value in correlating experiments and
theoretical simulations is still yet to be demonstrated beyond preclinical investigation, but
future efforts in computational modeling for rational design will reduce the time to clinical
investigation.
In the following chapter, we present the development of molecular models for
amphiphilic hyaluronic acid derivatives by systematically investigating the change in
physicochemical properties and supramolecular behavior as a function of hydrophobic
modification with alkyl chains of varying length. We support our findings through
experimental analysis with dynamic light scattering (DLS), arguing that the trends
observed in computational modeling correspond to supramolecular behavior in bulk
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solution. Furthermore, we observe and describe a relationship between the length of the
alkyl chain introduced to HA and the formation of hydrophobic domains, which affects the
potential for use of such amphiphilic polymer as a delivery system. Finally, we conclude
by placing our work and insights into the context of the theoretical design process for drug
delivery systems.
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Chapter 5: Experimental
Materials and Methods
Materials
N-hydroxysuccinimide

(NHS),

1-ethyl-3-(3-dimethylamino)propyl)carbodiimide

(EDC), hexylamine, dodecylamine, and octadecylamine were purchased from SigmaAldrich (St. Louis, MO). N,N-dimethylformamide (DMF) was purchased from Fisher
Scientific (Pittsburgh, PA). Ethanol was purchased from UNMC internal supply. Sodium
hyaluronate (HA) was purchased from Lifecore Biomedical (Chaska, MN).

Molecular Dynamics Simulations
Molecular dynamics simulations were performed using GROMACS 4.6 with the
GROMOS 53a6 force field and the SPC water model 217. The HA model and FF interaction
parameters were adopted from the G53A6CARBO united atom FF218,219, in which the CH,
CH2 and CH3 moieties are treated as a single, united interacting site. Each polymer model
was simulated for 260 ns. A single polymer chain in a linear extended conformation was
placed in a rectangular cell of 20 nm x 15nm x 15nm, filled with approximately 105 water
molecules.
To keep physiological ionic strength 0.1 M NaCl was added to aqueous solution.
All the MD simulations were carried out at a constant number of particles, constant
pressure of P = 1 atm, and constant temperature T = 303 K (the NPT ensemble). The
reference temperature of 303 K was kept constant using the velocity rescaling weak
coupling scheme 220 with a coupling constant τ = 0.1 ps. The initial atomic velocities were
generated with a Maxwellian distribution at the given absolute temperature. Periodic
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boundary conditions were applied to all three directions of the simulated box. Electrostatic
interactions were simulated with the particle mesh Ewald (PME) approach

221

using the

long-range cutoff of 0.8 nm. The cutoff distance of Lennard-Jones interactions was also
equal to 0.8 nm. The MD simulation time step was 1-2 fs with the neighbor list updates
every 10 fs. All bond lengths in the HA chain were kept constant using the LINCS routine
. The MD simulations were carried out using the GROMACS set of programs, version

222,223

4.6 198. Molecular graphics and visualization were performed using VMD 1.8.6 224.
The analysis was performed using GROMACS tools. The radius of gyration, headto-tail distance, number of polymer-polymer hydrogen bonds, number of polymer-solvent
hydrogen bonds, and solvent-accessible surface area were extracted from the trajectory
files and plotted using GraphPad Prism 7.0 (GraphPad Software; La Jolla, CA).

Synthesis of Hyaluronic Acid-Based Amphiphiles
Amphiphilic hyaluronic acid (HA) polymers were synthesized as described in previous
reports 27. Briefly, 40-45 mg HA (MN = 10-20 kDa, 100 kDa) was dissolved in 1:1 ultrapure
water and DMF along with 30 mg of NHS and 30 mg of EDC. After mixing for 30 minutes
to activate the HA carboxylic acid groups, 5-10 weight percent of hydrophobic reagent
(hexylamine, dodecylamine, or octadecylamine) was added to the HA solution and allowed
to react for 24 hours. Samples were then removed and placed in 3500 MWCO dialysis
tubing and dialyzed against 1:1 water and ethanol for 4 exchanges over 24 h, then against
pure water for 8 exchanges over 48 h to remove any impurities. Finally, samples were
frozen and freeze dried for later use. Hereafter, hexylamine-modified HA is referred to as
hexHA (Figure 18A), dodecylamine-modified HA is referred to as dodHA (Figure 18B),
and octadecyl-modified HA is referred to as ocdHA (Figure 18C). Figure 19A shows a
graphical representation of the placement of deprotonated glucuronic acid (red) and
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protonated glucuronic acid (blue) for the 50% dissociated HA model. N-acetylglucosamine
is colored mauve for reference. Figure 19B shows the placement of hydrophobically
modified glucuronic acid moieties chosen at random (green) with unmodified, protonated
glucuronic acid moieties (blue) and unprotonated glucuronic acid moieties (red). Nacetlyglucosamine moieties are shown in mauve.

Analysis of HA conjugates
Amphiphilic HA conjugates (hexHA, dodHA, and ocdHA; Figure 18) were analyzed
on a Bruker Avance 600 MHz NMR spectrometer with TXI Cryoprobe at 25 °C with 64 to
128 scans, 8192 to 16 384 data points, and 10−12 s relaxation delay. Samples were
analyzed in DMSO-d6 (Cambridge Isotope Laboratories, 99.9% D). Data was processed
in Mnova NMR (Escondido, CA).
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Figure 18: Structures of HA and hydrophobically modified HA derivatives.

Figure 19: Visual schematic of the HA modification for simulations.

Dynamic Light Scattering
To prepare samples for DLS, amphiphilic HA conjugate was dissolved in ultrapure
water for a stock solution concentration of 1.0 mg/mL and allowed to equilibrate for at least
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24 h, then lower concentrations were prepared from this stock solution and allowed to
equilibrate for at least four hours and stored at 4 ºC prior to analysis. Samples were
prepared in concentrations ranging from 0.008-1.0 mg/mL for DLS analysis using a
Malvern ZetaSizer Nano ZS (Malvern Instruments; Malvern, UK). Ten independent
measurements were made for each sample concentration at a temperature of 25 ºC. Data
were exported in CSV format and analyzed in GraphPad Prism 7.0 software (GraphPad
Software; La Jolla, CA).

Results and Discussion
Influence of degree of dissociation on HA dynamics
Investigation of HA self-assembly dynamics began with ensuring conformity
between

experimental and

theoretical

approaches.

Prior

to

investigating

the

hydrophobically modified HA derivatives, simulations of HA at different degrees of
dissociation were performed to examine differences in polymer dynamics due to
protonation of the carboxylic group. Due to the presence of carboxylic groups on HA, the
degree of dissociation can potentially affect the polymer-polymer and polymer-solvent
interactions through hydrogen bonding.
HA with the polymer chain length of 26 units was modeled computationally in the
completely dissociated state and with the degree of dissociation of 20% (which, depending
on its final concentration, corresponds to the experimental degree of dissociation of
aqueous HA with its pKa reported to be 2.9

). Figure 19 visually demonstrates the

225

substitution and deprotonation positions for simulation of HA.

Using these models,

simulations were performed to compare the protonated and deprotonated dynamics.
Figure 20A details the changes in the radius of gyration during 260 ns of simulations and
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Figure 20B shows the frequency distribution of the radius of gyration values for the full
trajectory shown in Figure 20A.
Sites of substitution and deprotonation were chosen at random. Since ligands are
conjugated to HA through the carboxylic groups on the glucuronic acid moieties and these
moieties are active in hydrogen bonding, difference in the degree of dissociation,
correlating to the effective pH of the environment, could influence polymer behavior. The
radius of gyration was found not to be significantly different between the two samples by
performing a Kolmogorov-Smirnov test (p>0.05). Furthermore, the number of hydrogen
bonds between the polymer and the surrounding water molecules was not found to be
significantly different. These data indicate that the degree of dissociation did not
significantly influence the results obtained from simulations of amphiphilic HA.

Figure 20: Dynamics of a single 10 kDa HA polymer chain of 20% and 100% dissociation
in water.

80

Radius of gyration and end-to-end distance analysis
Examining the radius of gyration is the most straight forward method to investigate
the effects of hydrophobic modifications on HA. MD simulations were performed for 260
ns to observe the conformational change from linear to random coil conformation of the
modified and unmodified HA polymers. Three modified HA polymers were considered:
hexHA, dodHA, and ocdHA (Scheme 1, were n=19 and m=7, respectively). As shown in
Figure 20A, the radius of gyration for both hexyl- and octadecyl-modified HA reaches a
stable radius of gyration of around 2 nm. When compared to unmodified HA (4 nm), these
radii are much smaller, demonstrating a more compact conformation as a result of
hydrophobically-driven intramolecular interactions. Furthermore, the distributions of
25,000 samplings of Rg taken from 150-260 ns (Figure 21C) indicate a relatively less
polydisperse sampling and a narrower distribution than that of unmodified HA. The
difference between ocdHA and hexHA is noteworthy in that the ocdHA sample exhibits a
smaller distribution of Rg values after collapsing to coil conformation, likely due to the
greater influence of hydrophobic packing on driving the compactness of the overall
molecule. The much greater length of the hydrophobic chain contributes to the formation
of more defined hydrophobic pockets inside the coil, ultimately resulting a more stable
conformation.
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Figure 21: Dynamics of single polymer chains of 10 kDa alkyl-substituted HA.
The Rg of dodecyl-modified HA exhibits less pronounced conformational changes
over the course of the simulation than the hexyl- or octadecyl-modified samples. While
hexHA and ocdHA both reach stable conformations, dodHA continues to fluctuate at a
higher Rg and more closely resembles the behavior of unmodified HA. This difference
suggests a divergence in the hydrophobic packing of the molecule when compared to
ocdHA. When transitioning from linear to random coil conformation, the effect of
hydrophobic packing of the alkyl chains associating can cause intramolecular strain. We
anticipate that the difference in behavior between dodHA and the other alkyl derivatives
of HA is a result of increased strain that is not overcome by hydrophobically-driven
collapse. HexHA would have the lowest degree of intramolecular strain, thus being more
amenable to hydrophobic collapse, whereas the dodHA polymer would experience
significantly more strain than hexHA without the stronger hydrophobic interactions as seen
in ocdHA.
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The head-to-tail distance is also an important measure of compactness of the
polymers in simulation. Similar to the Rg results, the head-to-tail distance is more compact
for hexHA and ocdHA, whereas dodHA is more closely comparable to unmodified HA. All
modified HA polymers were substituted at the same positions along the polymeric
backbone to eliminate any variation due to difference in location of hydrophobic moiteties,
and as such, the difference between hexHA, dodHA, and ocdHA in the head-to-tail
distance is less pronounced than the Rg as shown in Figure 21B. However, the distribution
of the samplings between 150-260 ns (the gray-shaded region) clearly demonstrates a
narrower distribution of distance for the hexHA and ocdHA samples than the distributions
of the dodHA or HA samples as shown in Figure 21D.
The change in conformation from linear to coil is illustrated with snapshots from
the MD simulations in Figure 22. This transition is driven by hydrophobic collapse,
ultimately leading to the compact coil formations observed towards the end of the
simulations. Furthermore, these snapshots of the polymer amphiphiles conformations help
to graphically illustrate the changes in Rg and end-to-end distance explained in this
discussion. Of particular note are the final conformations of each molecule; while hexHA
and ocdHA form relatively more compact conformations, dodHA exhibits behavior
indicative of less favorable collapse and compaction as a result of intramolecular strain.
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Figure 22: Snapshots from MD simulations for alkyl-substituted HA derivatives at time
intervals progressing to 240 ns.
These simulations show that as the polymers transition from linear to random coil
conformations, the nature of the hydrophobic moiety contributes to polymer packing and
the resulting Rg. Water molecules and buffering ions are not shown for clarity. Hydrophobic
moieties are color coded, while the polymer backbone is shaded gray for emphasis.
To support and add rigor to the results from our simulations, we performed
additional independent simulations to ensure the repeatability of our results. Figure 23
shows the results of such simulations performed using the same starting models used to
create Figure 18, as well as self-assembled polymer configurations from the original
simulation. Figure 23A and B show the change in radius of gyration along the simulation
trajectories.

Figure 23C and D show the change in head-to-tail distance along the

simulation trajectories. Run 1 is the initial simulation represented and discussed earlier in
the results and presented in Figure 21. Run 2 is an additional independent simulation
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Figure 23: Additional simulations of hydrophobically modified HA.
performed using the initial linear configurations of the polymers (the same starting
geometries that were used for Run 1). Run 3 is an independent simulation using the
equilibrated polymer configurations from the Run 1 at 160 ns. The hexyl and octadecyl
derivatives coincide with the behavior observed in Run 1 closely. In Run 2, the dodecyl
HA tends to be more compact than in Run 1; however, at a later stage it exhibits further
partial disassembly. Being restarted from the intermediate equilibrated configurations from
Run 1, all three systems closely follow their behavior observed in earlier simulation.
Overall, these additional simulations support our observations and demonstrate
reproducibility of the results. In these simulations, dodecyl-modified HA continues to show
more instability in self-assembly behavior that potentially leads to less tightly packed
nanoaggregates of larger sizes.
Additionally, analyses were performed on the trajectories to evaluate the effect of
hydrophobic substitution on the glycosidic dihedral angles (Figure 24) as shown in Figure
25. Based on the results of our simulations, introduction of alkyl substituents does not
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cause significant deviation of the glycosidic dihedral angles from the typical value of
±120°226.

Figure 24: Schematic illustrating the dihedral
angle that was analyzed for all samples.

Figure 25: Distribution of the dihedral angles for (A) hexHA, (B) dodHA, (C)
ocdHA, and (D) comparison between the distribution of the dihedral angles for all
three derivatives at 100, 200 and 260 ns. No significant difference is noticed, and
all glycosidic dihedral angles values fluctuate around ±120°.
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Investigation of solvent-accessible surface area
The results illustrated in Figure 22 coincide with changes in the solvent-accessible surface
(SAS) area of the polymer stands. The total, hydrobic, and hydrophilic solvent-accessible
surface area were extracted to examine their changes as the polymers transmute
conformation over the course of the simulation. As the conformation changes, the
hydrophobic packing of the alkyl chains results in the formation of hydrophobic domains
that are shielded to varying extents by the hydrophilic components of the polymer.
Interestingly, dodHA exhibits negligible change in total surface area while both hexHA and
ocdHA show an overall decrease in solvent-accessible surface, which is consistant with
the trend observed for the radius of gyration in Figure 21. Correlation between Figure 22
and Figure 26 can also be visually inferred by observing that the relative compactness of
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Figure 26: Change in total (A), hydrophilic (B) and
hydrophobic (C) solvent accessible surface area of
the HA polymers during simulations.
the polymer at the different timepoints in the simulation correlates strongly with the
solvent-accessible surface.
From the discussion of Rg and head-to-tail distance gleaned from Figure 21, the
difference in compactness between hexHA and ocdHA is not unambiguous. However,
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significant difference in dynamics of normalized hydrophobic SAS area between ocdHA
and hexHA (Figure 27) better illustrates the tighter packing of the former. From Figure 27,
the impact of hydrophobic modification on the ratio of solvent-accessible surface area
becomes apparent, especially for the ocdHA species. The compactness of the
hydrophobic pockets and the differences between hexHA and ocdHA are visually apparent
in Figure 22 which correlates well with Figure 27. In Figure 27, A shows the unmodified
HA control, (B) hexHA, (C) dodHA, and (D) ocdHA, allowing comparison between the
modified species and the unmodified control. While the Rg for hexHA and ocdHA remain
similar throughout the simulation, the interior environment and the hydrophobic domains
created differ greatly. As the HA polymers collapse to form hydrophobic pockets, it is
thermodynamically favorable and expected that the hydrophobic SAS area would
decrease as a fraction of the total SAS area. The hydrophobic SAS of ocdHA decreases
from 47% to 39%, whereas its hydrophilic SAS increases from 53% to 61% as seen in
Figure 27D.
The most insightful observation from the MD analysis of the SAS area for the
samples is the difference in hydrophobic contribution to the total SAS when compared to
the other modified polymers. Unlike previously discussed results for the radius of gyration
in Figure 21, the hexHA and dodHA samples appear to be in accordance whereas the
results of MD simulations of ocdHA deviate from the other samples. The trend of
decreasing hydrophobic SAS area is very apparent for the ocdHA sample, where it
decreases by approximately 20 nm2 while the total SAS area decreases by only
approximately 30 nm2. The behavior of ocdHA clearly demonstrates the hydrophobic
collapsing and the tighter distribution of Rg when compared to dodHA and hexHA. Despite
significantly bulkier hydrophobic moiety, the hydrophobic solvent-accessible surface
decreases to the level of that of hexHA. When loading hydrophobic drugs into a
nanoparticle drug delivery system, the nature of the hydrophobic pockets in the delivery
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system dictates loading efficiency and controlled release via passive diffusion of the
drug.23,168 Thus, when formulating drugs through physical entrapment in polymeric
nanoaggregates, an understanding of the fundamental physicochemical properties of the
amphiphilic polymer and the hydrophobic pockets created during the collapsing or
aggregation process is of paramount importance.

Figure 27: Changes of hydrophobic (red) and hydrophilic (blue) solvent accessible surface
as fractions of the total solvent accessible surface of HA and alkylated HA derivatives.
Our experiments only investigate the effects of the alkyl chain length of modified
HA using aliphatic hydrocarbons as hydrophobic moieties. The results from the analysis
of the change in the Rg and the solvent-accessible surface area demonstrate that the
length of the alkyl substitution dictates not only the conformation of the polymer coil, but
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also the stability of the hydrophobic pockets, and demonstrates the dependence of
hydrophobic collapse on intramolecular strain. HexHA, while forming a tightly compact coil
structure when compared to dodHA or unmodified HA, does not exhibit enough
intramolecular strain to significantly inhibit the formation of hydrophobic pockets inside the
coil. Upon moving to the more hydrophobically modified dodHA, one would expect a more
compact or more stable conformation than hexHA due to the contribution of additional
alkyl chain length. However, a much less defined coil conformation is observed, possibly
due to intramolecular (steric) strain limiting the variability conformational contortions.
OcdHA, which has the longest alkyl chains and a greater initial hydrophobic surface area,
exhibits the outcome of highly favorable hydrophobic collapse, potentially less inhibited by
or overcoming the effects of intramolecular strain.
The effect of the degree of alkylation was also investigated computationally. To
evaluate if the substitution ratio affects the polymer behavior in silico, models of HA
amphiphiles were constructed with 50% substitution with alkyl chains. Simulations were
performed for 150 nanoseconds, and distributions of the values were taken between 50150 ns to compare to Figure 20. Figure 28A shows the end-to-end distance data from the
simulation results, and the distribution of samplings from 50-150 ns are shown in Figure
28B. The radius of gyration quickly reaches a stable state in Figure 28C, and the
samplings from 50-150 ns are shown in Figure 28D. The more substituted HA derivatives
shown here reach a stable radius of gyration more quickly than the less substituted
derivatives shown in Figure 20. However, the same trends observed for the less
substituted HA amphiphiles are observed with their 50% substituted analogs. HA
derivatives with 50% alkyl chain substitution were constructed and simulated, producing
the results shown in Figure 28. The highly substituted HA systems behaved similarly to
those with the experimentally relevant degree of alkylation as previously discussed. The
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primary difference was that a higher degree of substitution resulted in reaching
conformation equilibrium more quickly. Additionally, the Rg of all samples appears to
behave uniformly. Despite the differences in the alkyl chain length, the degree of alkylation
overcomes limitations in conformational change, in contrast to the MD simulations with
lower conjugation ratios of alkyl chains.

Figure 28: Simulations of hydrophobically modified HA at 50% substitution.

Dynamic light scattering
The computational simulations we describe are limited to a single polymer strand and do
not provide certainty about the behavior of such materials when prepared experimentally
in bulk solution where multiple polymer molecules are able to associate with each other.
By comparing our computational findings with experimentally obtained results from bulk
solutions of the modified polymers, we show that in silico methods of investigating polymer
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amphiphiles for drug delivery applications can result in more optimally formulated
nanomedicines. Samples of hexHA, dodHA, and ocdHA were prepared and analyzed
using dynamic light scattering to observe the behavior of the polymers in bulk solution. As
the amphiphilic polymers interact with each other and form nanoparticles, the
measurement of the behavior of single polymer strands is not possible, however the
behavior of these aggregates can be related back to the simulation results of the individual
polymers as presented in Figure 21. The substitution ratio (degree of alkylation) was
determined experimentally by NMR. Samples of 10 kDa and 100 kDa hexHA, dodHA, and
ocdHA (6 samples in total) were analyzed to determine the molar ratio of the hydrophobic
moiety. Figure 29A shows the spectrum for 10 kDa hexHA and Figure 29B shows the
spectrum for 100 kDa hexHA. Figure 30A shows the NMR spectrum for 10 kDa dodHA
and Figure 30B shows the NMR spectrum for 100 kDa dodHA. Figure 31A shows the NMR
spectrum for 10 kDa ocdHA, and Figure 31B shows the NMR spectrum of 100 kDa HA.
The results from NMR analysis are presented in Table 4.

Conjugate

HA Molecular Weight
10 kDa

100 kDa

hexHA

25.22%

31.81%

dodHA

12.03%

13.07%

ocdHA

10.80%

21.46%

Table 4: Molar ratios of alkyl chains to hyaluronic acid calculated from NMR analysis.
Ratios were calculated from NMR peaks as described by Hill, et al.27
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Figure 29: NMR of hexylamine-modified HA samples.
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Figure 30: NMR of dodecylamine-modified HA.
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Figure 31: NMR spectra of octadecylamine-modified HA.
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The behavior of amphiphilic HA conjugates in bulk solution closely resembles the
results obtained from simulation studies of the individual polymer components as shown
in Figure 32. The first explicit correlation observed is the trend of nanoparticle mean size
and standard deviation when compared to the computationally determined Rg of the
constituent amphiphile (Figure 32A). In accord with the relative stability of the Rg for both
hexHA and ocdHA, the standard deviation in mean nanoparticle size (385 ± 30 nm and
175 ± 15 nm, respectively) for each of these experimental samples (Figure 32A) exhibits
trends parallel to those observed for both Rg (1.84 ± 0.16 nm and 1.64 ± 0.07 nm,
respectively) and head-to-tail distance observed in silico. Assent in behavior between two
different polymer lengths prepared experimentally reinforces the similarity in trends
observed between the theoretical and experimental results. Two sets of amphiphilic
conjugates were prepared—10 kDa and 100 kDa—to determine if the polymer length
affected the behavior observed after hydrophobic modification. Although simulations were
performed using only 10 kDa polymer chains due to computational limitations, the effects
of hydrophobic modification on the stability and size are distinguished for the 100 kDa
samples prepared experimentally (Figure 32) and align well with the observations of 10
kDa samples. In particular, the standard deviation from the mean hydrodynamic radius
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Figure 32: Dependence of nanoparticle size,
polydispersity index and scattering intensity upon the
hydrophobic ligand chain length

observed for the most compact ocdHA samples was 15 nm and 20 nm for 10 kDa and 100
kDa variants, respectively.
The experimental results obtained for ocdHA samples highlight the dependence of
the formation and stability of hydrophobic pockets on the physicochemical properties of
the hydrophobic moiety. The small mean hydrodynamic diameter and narrow size
distribution also clarifies our investigation of the formation of hydrophobic pockets within
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the aggregates and relates strongly to our computational results. When comparing the
ocdHA and hexHA samples, the Rg (1.84 vs. 1.64 nm), normalized hydrophobic solventaccessible surface area (0.43 vs. 0.39), and mean hydrodynamic radius (385 nm vs. 175
nm) suggest a distinct difference between the hydrophobic pockets formed inside the
aggregates, contending that the ocdHA samples produce more well-defined and stable
hydrophobic regions than the hexHA or dodHA.
Supramolecular behavior as a function of individual strand properties is supported
through the concentration-dependent intensities obtained from DLS for the HA derivatives
shown in Figure 33. The scattering intensity depends on the size, shape, and number of
particles in solution, and therefore the DLS data obtained shows that the ocdHA samples
produce smaller, more tightly aggregated nanoparticles in bulk solution. Figure 33 details
the scattering profiles as a function of concentration for both 100 kDa and 10 kDa variants
of the three amphiphilic HA derivatives. When comparing HA derivatives of the same
concentration, the scattering intensities differ greatly, with ocdHA producing the highest
scattering intensities. Since scattering intensity in DLS is proportional to the Brownian
motion of the particles in solution, the small standard deviations suggest better colloidal
stability and more uniform particles than the dodHA or hexHA samples.
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Figure 33: Dynamic light scattering of the HA amphiphiles.
The correlations observed between our theoretical and experimental work are
supported by previously published insights171,227–229 and expand the understanding of the
self-assembly dynamics of HA-based materials. Where others have investigated the
computer-aided formulation design,170,173,230,231 including HA-based system,229 our work is
the first example of systematically investigating the effects of hydrophobic modification on
single chain and supramolecular dynamics. As new drug delivery systems based on
polysaccharides are developed, computational methods for design and characterization
will be useful to shorten development time.
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While there are a few examples of FDA-approved nanomedicines,96,232 more
research into the fundamental science of nanomedicine will help new nanoformulations
translate into clinical use.93,109,120,233 Empirical and computational methods to evaluate
nanomedicine formulations theoretically, before experimental investigation, are gaining in
popularity, but still require further development to achieve widespread use. Our work
contributes to a growing body of research supporting the use of theoretical methods to
predict the self-assembly properties of nanomaterials for formulation.
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Chapter 6: Conclusions and Future Directions
Hyaluronic acid is a promising molecular platform for nanomedicine.234 Stemming
from innate biocompatibility and targeting to the cell surface receptor CD44, HA has been
used in a number of imaging and therapeutic agent formulations, both as a supramolecular
scaffold and targeting ligand.35,36,235 When used as a self-assembled formulation, the
choice of hydrophobic ligand and additional targeting moieties plays an important role in
function and structure.133,236
Modeling hyaluronic acid presents several challenges, most of which derive from
the inability to synthesize HA without using bioengineering or bioproduction methods. The
relatively high dispersity of HA polymers when compared to synthetic polymers like
polystyrene adds experimental error and reduces the accuracy of simulations.237 However,
value is still seen from the simulations, especially considering the potential to simulate
interactions between polymers and therapeutic agents. With the greater understanding of
the importance of modification in hyaluronic acid-based systems, new formulations and
contrast agents can be designed and improved with the ultimate goal of reaching clinical
adoption.
We report the fundamental investigation of hydrophobically modified HA
derivatives and the physicochemical properties that influence their collapse into coil
conformations when simulated in silico, as well as experimentally observed aggregation
of multiple polymer strands into nanoparticles. Using a series of alkyl-modified HA, we
investigate in detail the influence on alkyl chain length on the radius of gyration, head-totail distance, and solvent-accessible surface area, ultimately relating theoretical insights
to behavior of real polymers in bulk solution.
Molecular dynamics simulations revealed a distinct correlation between alkyl chain
lengths and HA conjugate stability in the form of Rg and solvent-accessible surface area
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when individual amphiphilic polymers solvated in water were modeled. When compared
to unmodified HA, which is innately hydrophilic, amphiphilic HA conjugates quickly
transitioned to random coil conformations driven by hydrophobic collapse and the
formation of hydrophobic domains. The definition of the hydrophobic domains depends
heavily on the properties of the polymer, where conformational transitions are driven by
the alkyl chain length but inhibited by forces such as intramolecular strain. The delicate
balance between hydrophobicity and steric hindrance calls to attention a new factor for
consideration in the design of supramolecular assemblies for drug delivery applications.
Our computationally obtained insights are substantiated through experimental
results. Samples of each HA derivative were prepared in two polymer chain lengths to
elucidate any dependence of aggregation or conformational trends for polymer molecules
of different sizes. The behavior observed for experimental samples—analysis in bulk
solution rather than individual strands—correlated to the trends exposed in silico; where
Rg and relative hydrophobic solvent-accessible surface area correlate to compactness and
stability of coil conformation, nanoaggregates in bulk demonstrate stability and degree of
hydrophobic domain definition to be dependent on the properties of the individual polymer
components. Ultimately, these results support our hypothesis that the dynamics of
supramolecular assemblies composed of polymeric amphiphiles mirror the characteristics
of its components.
Our work is a fundamental investigation aiming to improve the understanding of
factors that should be considered when designing a drug delivery system from amphiphilic
polymers. Elucidating the properties of structures that are poorly understood and difficult
to picture will aid in the optimization of formulations for a variety of aspects, and the
insights gained herein are a step forward in creating a paradigm for physicochemical
design of nanomedicines.
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Computational Simulation and Nanomedicine
This chapter demonstrated the first attempt at using computational methods to
better understand the dynamics of hydrophobically modified hyaluronic acid in the
perspective of drug delivery and nanomedicine. The use of molecular dynamics to model
polymeric systems, in this case using only single strand systems, was correlated to
experimental measurements using dynamic light scattering. We do acknowledge,
however, that single-strand simulations are limited in application to bulk solution
conclusions. As discussed in Chapter 4, the evolution in design paradigms for
nanomedicine will require accurate simulations of larger, more complex systems.
To build on the work presented in this thesis, and to extend the research direction
presented in Chapter 5, a subsequent publication investigated the simulation and
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Figure 34: Flow chart for
hydrophobically-modified HA.

the

investigation

of

spectroscopy of more complex hydrophobic HA derivatives.238 Figure 34 is taken from our
recent publication to graphically demonstrate the logical rationale for using simulations
and spectroscopy to design HA-based nanomaterials. Beginning with the simulation of
single polymer strands, lead candidates are identified for further investigation. Building on
our previous work, which focused solely on modification by aliphatic hydrophobic moieties,
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Figure 35A shows a schematic overview of aromatic ligands to be investigated with HAbased materials. Figure 35B demonstrates the simulation trajectory for these new HA
amphiphiles using the same methodology from Figure 20. In Figure 35C, visual
representations of the single strands are given, which provides insight in a similar way to
Figure 21.
A key observation in the simulations of HA amphiphiles incorporating aromatic
moieties is the formation of hydrophobic pockets with π-π stacking, especially for the pyHA
species. In Figure 35C, π-π stacking is readily visible. However, as previously noted,
single strand simulations are limited in scope when investigating behavior of complex,
multicomponent

systems.

Addressing

this

concern,

Figure

36

presents

two

multicomponent systems, with Figure 36A showing a system of 22 10kDa strands of
ocdHA and Figure 36B showing a snapshot of simulation of 22 strands of pyHA. In each
of these simulations, distinct hydrophobic pockets are formed, and π-π stacking is clearly
visible within the pyHA sample.
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Figure 35: Simulation of aromatic hydrophobically modified HA.
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Figure 36: Difference between aromatic and aliphatic hydrophobic HA
modification.
To use simulations for insights and design of new nanocarriers, an additional
investigation into heterogenous, multicomponent systems is required. Figure 37 presents
screenshots of interactions between ocdHA (Figure 37A and C) and pyrene-modified HA
(Figure 37B and D) with solvatochromic dyes to provide additional information into the
interactions between drug-like molecules and HA-based amphiphiles. In these
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Figure 37: Multicomponent simulations of HA and solvatochromic dyes.
simulations, two dyes of similar molecular structure are investigated as surrogate drugs in
formulation with the HA amphiphiles. We used 3-hydroxychromone based dyes DOAF
and DPAF to demonstrate the difference between aromatic and aliphatic association in
the complex systems, the structures of which are presented in Figure 38. By using
fluorescent dyes, further experiments can be conducted using fluorescence spectroscopy
to evaluate and compare to simulations. Further reading in the application of fluorescence
to simulations is reported by Svechkarev, et al.76

Conclusion
In this chapter, we presented molecular dynamics simulation to investigate and
explain the dynamics of hydrophobically modified HA to better develop future formulations
for imaging and drug delivery. Expanding on this research, the new perspectives
developed in this research will enable better use of HA as a building block for future
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formulations. New research is already being conducted to examine larger and more
relevant systems to drug delivery research based on our findings.238

Figure 38: Structure of dyes used as surrogate drugs for multicomponent
systems.
Molecular dynamics, although of less resolution than quantum mechanical
methods, offers insights into the interactions between macromolecules and other
components of drug delivery systems. The myriad of programs and strategies available to
study the large systems typically encountered in drug delivery research enables numerous
potential avenues of theoretical investigation. As computational resources become more
abundant and powerful, larger systems and higher resolution simulations will provide
insight into the fundamental physicochemical properties that are important to successful
nanoformulation.
While computational methods for the evaluation of small molecules and proteinligand docking have existed for decades, there are currently no computer-based
evaluation programs for nanomedicines, commercial or otherwise.239,240 Where virtual
high-throughput virtual screening has been demonstrated to be an effective tool for the
discovery of new drug candidate molecules, expanding the tools and methods currently
available to evaluate and design new nanoformulations will help to expedite development
and identification of better therapeutic formulations.125,230 To date, no efforts have been
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made to evaluate a library of polymeric nanomaterials, and through the systematic
computational investigation of new polymer systems as described in this dissertation will
address previously unanswered questions involving the effects of the various inter- and
intra-molecular interactions present in polymeric drug delivery systems.
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